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ABSTRACT OF THE DISSERTATION
Perinatal Hypoxia Exposure on the Developing Heart: the Role of
Endothelin-1
Alexandra Paradis
Doctor of Philosophy, Graduate Program in Pharmacology
Loma Linda University, March 2015
Dr. Lubo Zhang, Chairperson
Heart disease is the leading cause of death worldwide. Numerous epidemiological
and animal studies have indicated that an adverse intrauterine environment is associated
with increased risk for cardiovascular disease. Therefore proper cardiac development is
imperative in optimizing cardiac function throughout life. A key process in determining
cardiomyocyte endowment, and thus cardiac function, is the period of terminal
differentiation. This involves the maturation of cardiomyocytes and is essential to heart
development, however acceleration of this process may alter cardiomyocyte endowment.
Hypoxia/anoxia is a major perinatal stressor that often afflicts the fetus as well as the
premature infant, and leads to the production of endothelin-1. Our study aims to test the
hypothesis that perinatal hypoxia exposure induces a premature terminal differentiation
of cardiomyocytes, focusing on the role of endothelin-1 and the underlying epigenetic
and molecular mechanisms. We established two rat models for this study: 1) ex vivo
endothelin-1 treatment of fetal cardiomyocytes, and 2) in vivo anoxia episodic treatment
of neonatal rats. In the first part of our study, we demonstrated that endothelin-1 exposure
promoted premature terminal differentiation of cardiomyocytes. Furthermore, this effect
was associated with an increase in global DNA methylation. Our next section of the study
simulated the major clinical problem of premature birth and the anoxic episodes that
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often accompany it. We demonstrated that early neonatal anoxic episodes decrease
cardiomyocyte proliferation during the first two weeks of life. Moreover, this loss of
proliferation ultimately resulted in a decrease in cardiomyocyte endowment by day 14
when the heart is essentially mature. Furthermore, the ETA-receptor appears to be a key
mediator of these effects. Lastly, our third section identified several proteins in the fetal
cardiomyocyte that were altered due to endothelin-1. Many of the proteins are associated
with proliferation and survival and may help elucidate a molecular mechanism for
endothelin-1-induced cardiomyocyte maturation. These findings provide new insights in
the understanding of hypoxia-induced terminal differentiation of cardiomyocytes and the
role of endothelin-1 as well as the epigenetic and molecular mechanisms involved. This
study provides supporting evidence of the detrimental effects of perinatal hypoxia/anoxia
on cardiac development, and thus function for a lifetime.
!
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CHAPTER ONE
INTRODUCTION
Developmental Programming of Health and Disease
It has been well established that an adverse intrauterine environment is associated
with an increased predisposition to cardiovascular disease (Barker, 1995, 1997, 2004).
Therefore this timeframe and critical environment is highly influential on the health of an
individual across their lifetime. Its influence can lead to structural and functional
adaptations of several organs, including the heart. Persistence of these adaptations can
increase vulnerability to disease later in life (Barker, 1990, 2004; Botting et al., 2012). A
study has shown that adult rats, which were exposed to an adverse environment in utero,
were more susceptible to ischemic injury when encountering a stress later in life (G. Li et
al., 2003).
In terms of the developing heart, an adverse environment may alter
cardiomyocyte number and be responsible for this increased susceptibility to
cardiovascular disease. In support, animal studies provide evidence that fetal stress
caused by hypoxia (Bae, Xiao, Li, Casiano, & Zhang, 2003; Botting, McMillen, Forbes,
Nyengaard, & Morrison, 2014), as well as other factors (Bubb et al., 2007; Corstius et al.,
2005; Giraud, Louey, Jonker, Schultz, & Thornburg, 2006), affects both the number of
cardiomyocytes and the ability of the heart to cope with stress later in life.

Heart Development and Cardiomyocyte Terminal Differentiation
Cardiomyocytes are the functional unit of the heart; therefore the number of
viable myocytes dictates cardiac function. The total cardiomyocyte population is
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determined early in life during the fetal development and around birth, with negligible
increases thereafter (Bergmann et al., 2009). Hence, preservation of cardiomyocyte
number will fortify the heart and allow adequate response to stress later in life.
It has long been held that the heart loses proliferative capacity soon after birth in
most mammals (Ahuja, Sdek, & MacLellan, 2007; Burrell et al., 2003; Clubb & Bishop,
1984). This timeframe is consistent with the conversion of cardiomyocytes from a
mononucleate to binucleate phenotype. Binucleation is a characteristic of terminally
differentiated cells that are unable to proliferate, whereas mononucleate cells continue to
cycle (Figure 1.1). Early in normal fetal development the majority of cardiomyocytes are
mononucleate, allowing growth to be achieved by proliferation. In the timeframe
surrounding birth, the heart maturation occurs in which mononucleate cells begin the
transition to a binucleate phenotype. The uncoupling of cytokinesis from karyokinesis
and ultimate exit of the cell cycle characterize the transition, resulting in binucleation (F.
Li, Wang, Capasso, & Gerdes, 1996). Subsequent increases in heart size are independent
of proliferation and the result of increases in individual cell size termed hypertrophy.
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Figure 1.1. Cardiomyocyte terminal differentiation. Early in development,
cardiomyocytes are mononucleate and exhibit cell cycle activity. As cardiomyocytes
become terminally differentiated, they progressively exit the cell cycle and the
percentage of binucleate cardiomyocytes is increased.!
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In humans, the fetal heart consists of mainly mononucleate cardiomyocytes and
thus is the time point in which most proliferation occurs. Prior to birth, binucleation
begins and by birth the heart is essentially mature. Similarly, sheep follow this pattern of
development, providing a close model for studying the heart. Rodents are another
commonly used model however it is to be noted that cardiomyocyte binucleation in
rodents begins and ends within the first two weeks after birth (F. Li et al., 1996). In all
these species, the adult heart contains the greatest amount of binucleate cells when
compared to the fetal and neonatal stage. However the percentage of binucleate cells
within the adult heart varies among species, as reviewed by Botting et. al. (Botting et al.,
2012). In humans, there is considerable debate on the amount of binucleate cells present
in the adult heart, with percentages ranging from 25 to 60 (Botting et al., 2012). Rodents
and sheep, on the other hand, have approximately 90 percent of the cardiomyocyte
population binucleated (Botting et al., 2012).
A rodent model is advantageous in studying heart development in that it allows
interventions to be performed after birth but while the heart is still immature. In this way,
a more direct effect of treatment on the individual newborn rats can be observed as
opposed to treatment performed in utero. The rodent heart reaches full maturation at
postnatal day 14 thus providing a two-week window for both performing treatment and
observing its effects on heart development and maturation. Therefore studying the
neonatal rat heart provides a model to study the equivalent maturation process that occurs
in both the fetal and preterm human heart.
The loss of proliferation and the increase of binucleate cardiomyocytes
characterize this transition to a terminally differentiated state. In the adult heart, the
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proliferative capacity of cardiomyocytes is lost, and the heart is known to exhibit only
negligible increases in cell number (Bergmann et al., 2009). Thus once this transition
occurs, the number of cardiomyocytes that will reside in the heart throughout the lifetime
of that individual is determined. While this is a normal transition, if it occurs too early or
at an accelerated pace, it may ultimately affect the number of cardiomyocytes endowed in
the heart.
At this point, the physiological importance of binucleation is still poorly
understood. A plausible explanation is that multinucleation optimizes cellular response,
enhancing cell survival when coping with stress (Anatskaya & Vinogradov,
2007). Another argument is that binucleation occurs in order to meet the high metabolic
demand of cardiomyocytes. As such binucleation plays an advantageous role in allowing
the cell to generate twice the amount of RNA in order to synthesize proteins (Ahuja,
Sdek, et al., 2007). Although the role of binucleation is unclear, the percentage of
binucleation can be used as a parameter to identify mature cardiomyocytes.

Potential Mechanisms of Terminal Differentiation
The molecular mechanisms responsible for cardiomyocyte binucleation remain
unknown. Considering the distinct characteristics between the two cardiomyocyte
phenotypes, it is apparent that a marked change in cell cycle activity must occur to
achieve binucleation. The process appears to be tightly associated with regulation of the
cell cycle, cytokinesis, and epigenetic mechanisms.
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Cell Cycle Regulation
Cell cycle regulators are differentially expressed within the mononucleate versus
binucleate state. Cardiomyocytes exit the cell cycle following binucleation and as such
are terminally differentiated. Cell cycle phases include gap phase 1 (G1), synthesis phase
(S), gap phase 2 (G2), and mitosis (M). The G0 phase provides an exit route from the cell
cycle in which the cells remain in an indefinite quiescent state. Molecules that determine
the rate of growth and proliferation include cyclin-dependent kinases (CDKs) and their
inhibitors (CDKIs). CDKs promote the cell cycle whereas CDKIs are known to inhibit
the cell cycle (Brooks, Poolman, & Li, 1998). During the fetal development, CDKs are
highly expressed within the heart and become downregulated in adulthood. Conversely,
the negative regulators of cell cycle, such as CDKIs, are then upregulated in the adult
heart (Pasumarthi & Field, 2002). The prominent CDKIs, such as p21, p27, and p57,
appear to play a role in the cardiomyocyte arrest of the cell cycle during development (as
reviewed in (Brooks et al., 1998)). In neonatal cardiomyocytes, targeting p21 and p27 via
siRNA knockdown promoted proliferation and progression of cells into the S
phase. Furthermore, the proliferation of adult cardiomyocytes was induced with the
knockdown of the three CDKIs: p21, p27, and p57 (Di Stefano, Giacca, Capogrossi,
Crescenzi, & Martelli, 2011). Maternal hypoxia has also been shown to downregulate
cyclin D2 and upregulate p27 expression, associated with a decrease in proliferation of
fetal cardiomyocytes (Tong, Xiong, Li, & Zhang, 2013).
A conserved splice variant of cyclin D2, D2SV, has been shown to induce
embryonic cardiomyocytes to exit the cell cycle while reducing the capacity to enter the
cell cycle. D2SV forms micro-aggregates that sequester cell cycle promoting proteins
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such as CDK4, cyclin D2, and cyclin B1, leading to cell cycle exit (Sun, Zhang, Wafa,
Baptist, & Pasumarthi, 2009). D2SV expression in the embryonic heart is higher than the
adult, contrary to expectations. The role of D2SV in negatively regulating proliferation,
underlines the inherent ability of the heart to autoregulate cell cycle activity. This
mechanism appears to be essential in optimizing cardiomyocyte number. Maintenance of
the balance between promotion and inhibition of the cell cycle is necessary to obtain the
full potential of the heart.
Liu et al. found that cyclin G1 expression in the mouse heart was low during fetal
(E18) and postnatal day 2, and was increased from day 4 on (Z. Liu, Yue, Chen, Kubin,
& Braun, 2010). The expression of this cell cycle protein corresponds with the
polyploidization of cardiomyocytes. This study demonstrated that overexpression of
cyclin G1 stimulated S-phase entry but blocked cytokinesis, the latter exhibiting a
stronger effect. By knocking-out cyclin G1, several pro-proliferative factors such as
proliferating cell nuclear antigen (PCNA), survivin, aurora B, and mad2 were
downregulated, suggesting that cardiomyocytes exited the cell cycle (Z. Liu et al., 2010).
Altogether, cyclin G1 expression is associated with cardiomyocyte transition and
increases multi-nucleation of these cells.
In rodents, cardiomyocyte transition occurs during the first two weeks of postnatal
life. The majority of myocytes are binucleate by postnatal day 7 (P7) (F. Li et al.,
1996). A recent study identified a potential candidate regulator involved in this process,
FAK-related non-kinase (FRNK) (O'Neill, Mack, & Taylor, 2012). FRNK is an
endogenous inhibitor of a major factor in cardiac growth, the focal adhesion kinase
(FAK). FRNK expression is increased during the first postnatal week, peaking at P7
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through P14. Together with the finding that bromodeoxyuridine uptake is higher in hearts
of FRNK null mice, these data implicate the role of FRNK in the suppression of cardiac
DNA synthesis in postnatal life. The FRNK null mouse hearts from P14 and P21 also
showed significantly elevated levels of Aurora-B, a protein necessary for cytokinesis
(O'Neill et al., 2012). The peak expression of this factor is consistent with the time frame
in which the majority of cardiomyocyte terminal differentiation occurs, providing
evidence that FRNK is a regulatory factor in the maturation of postnatal cardiomyocytes.
In addition, YAP1 is a main target for the Hippo kinase cascade, a key pathway in
regulating organ growth. When Yap1 is inactivated in the fetal heart, lethal hypoplasia
and decreased proliferation results (von Gise et al., 2012; Xin et al., 2011). In turn, YAP1
activation promotes proliferation of both fetal and postnatal cardiomyocytes while also
activating several cell cycle genes, such as cyclin A2, cyclin B1, and cyclin-dependent
kinase 1. Furthermore, the YAP1-induced cardiomyocyte proliferation requires
interaction with TEAD transcription factors (von Gise et al., 2012). The targeting of
Yap1 and upstream regulation of the kinase pathway leading to its activation appear to be
involved in cardiomyocyte terminal differentiation.
Oxidative stress can be induced by hypoxia; the role of reactive oxygen species
(ROS) on cardiomyocyte transition was evaluated using the scavenger, N-acetyl-Lcysteine (NAC). In vivo treatment of dams with NAC followed by in vitro treatment of
isolated cardiomyocytes resulted in increased proliferating cell nuclear antigen (PCNA)
expression and decreased binucleation. In addition, these NAC-treated cardiomyocytes
had decreased expression of p38 MAPK and Connexin43 (Cx43), whereas ROS was
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shown to activate p38 MAPK and increase expression of Cx43 (Matsuyama & Kawahara,
2011).
The regulation of cardiomyocyte transition is intricate and subjected to a complex
molecular mechanism. The involvement of numerous factors is necessary in maintaining
tight control of this significant event in the heart development. Notably, at any time point,
both stimulators and inhibitors are modulating the overall cardiomyocyte
population. While myocytes are actively proliferating in the developing heart it is
important to maintain mechanisms that will prevent excessive hyperplasia. As
cardiomyocytes become binucleate, a gradual decrease in proliferative factors and
simultaneous increase in inhibitors occurs. This extensive regulation illustrates the
significance of maintaining optimal cardiomyocyte number.

Epigenetic Regulation
Epigenetic modifications refer to changes in the expression of genes independent
of the DNA sequence. The intrauterine environment has been shown to play an active
role in affecting development via epigenetic mechanisms (Barker, 1990, 2004; Webster
& Abela, 2007; L. Zhang, 2005) and attributing to long-term adverse effects, known as
fetal programming. Initially, an organ can adapt to facilitate immediate survival and
functional compensation. However, sustained stress may result in compromised
physiology and/or tissue remodeling of an organ.
The epigenetic mechanisms involved in differentiation from progenitor cells to
cardiomyocytes have been investigated (Wamstad et al., 2012). However, few studies
have focused on the final step, i.e. terminal differentiation. It is known that the heart
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responds to environmental cues by modifying the epigenome (Patterson, Chen, Xue,
Xiao, & Zhang, 2010; Stein et al., 2011), however the specific details of this regulation of
cardiomyocyte maturation are lacking.
Polycomb Repressive Complex (PRC)2 is known to be involved in the
trimethylation of histone H3 at lysine 27 (H3K27me3). This complex is important in
regulating developmental processes and it is involved in suppressing genes leading to
cellular differentiation (T. I. Lee et al., 2006). A component of this complex, enhancer of
zeste (Ezh)2 is believed to ensure normal cardiac growth and adult activity (DelgadoOlguin et al., 2012). Ezh2 has also been shown to repress negative regulators of the cell
cycle such as Ink4a and Ink4b. He et al. inactivated the Ezh2 subunit of PRC2 and noted
hypoplasia and upregulation of Ink4a/b (He et al., 2012). Another PRC2 component,
EED (embryonic ectoderm development) is important for heart development. In fetal
cardiomyocytes, inactivation of EED results in perinatal lethal heart defects as well as an
upregulation of Ink4a, Ink4b, and other key developmental regulators (He et al., 2012).
This data, taken together, implicates the PRC2 complex and its components (Ezh2 and
EED) as regulators of proliferation in the heart, potentially via epigenetic modifications.
Kou and colleagues investigated other epigenetic mechanisms involved in the
maturation of cardiomyocytes (Kou et al., 2010). As noted before, terminal
differentiation and binucleation are inversely correlated to proliferation. A significant
increase in global methylation in the heart occurs during the neonatal period (Kou et al.,
2010), the same time frame for which binucleation occurs. Furthermore, expression of
DNA methyltransferases involved in de novo DNA methylation (DNMT3a and
DNMT3b) was significantly increased during the first 90 days of postnatal life. Inhibition
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of methylation with 5-azacytidine during neonatal day 7 and 10 resulted in a marked
increase in DNA synthesis and delayed maturation. Histone modifications were also
noted. Altogether these changes are associated with the terminally differentiated form of
cardiomyocytes, whereas a DNA methylation inhibitor reverted the myocytes to a less
differentiated state. This study provides evidence for a role of methylation in both the
reduction of proliferation and progression of cardiomyocytes to terminal differentiation.
Binucleate myocytes are both non-proliferative and terminally differentiated. Therefore,
it is plausible to hypothesize that binucleation might be associated with methylationinduced suppression of proliferation.
The discovery of the epigenome has expanded the possibilities of biological
regulation. Epigenetic modifications are employed in a variety of biological processes
including fetal programming of disease state as well as normal development. This role in
terminal differentiation of cardiomyocytes is of particular interest. These studies provide
evidence for the involvement of the epigenome in regulating cardiomyocyte proliferation
and maturation. This complex regulation appears to include DNA methylation and
histone modifications. With the observation that epigenetics is key in cardiomyocyte
maturation the focus should be on further elucidating these intricate mechanisms.

Perinatal Hypoxia and Heart Development
The intrauterine environment is physiologically “hypoxic” and necessary for the
development and function of organs in the fetal stage (Giaccia, Simon, & Johnson, 2004;
Ream, Ray, Chandra, & Chikaraishi, 2008; Webster & Abela, 2007). However severe
hypoxia can be detrimental to organ development (Webster & Abela, 2007), particularly
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an essential organ such as the heart. In the light of the field of fetal programming, this
perinatal stress may yield life-long detrimental effects on the heart.
Hypoxia is induced under a variety of conditions including nicotine exposure,
drug abuse, high altitude pregnancy, preeclampsia, anemia, and placental insufficiency
(L. Zhang, 2005). Reduced oxygen to the fetus can affect a number of developmental
processes and result in growth restriction (Jensen & Moore, 1997; McCullough, Reeves,
& Liljegren, 1977). Previous studies have shown that hypoxia directly reduces
proliferation in fetal rat cardiomyocytes, marked by reduced Ki-67 expression, a
proliferation marker (Tong et al., 2013). The downregulation of cyclin D2, a cell cycle
activator, and upregulation of p27, a cell cycle inhibitor, were associated with reduced
proliferation in hypoxia. Hypoxic conditions also upregulated the tissue inhibitor of
metalloproteinases, TIMP-3 and -4 (Tong et al., 2013). Upon knockdown, TIMP-3
increased cyclin D2 and Ki-67 in control cardiomyocytes, whereas TIMP-4 had no effect.
However, the hypoxia-mediated effects were blocked completely by TIMP-4 and only
partially by TIMP-3. This data implicates these inhibitors as potential candidates for
enhanced cardiac remodeling and reduced proliferation (Tong et al., 2013). A maternal
hypoxia model was also found to increase size and percent of binucleate cardiomyocytes
(Bae et al., 2003), as well as induce remodeling of the fetal and neonatal rat heart (Tong,
Xue, Li, & Zhang, 2011). A study by Jonker et al. using a fetal anemia sheep model
reported larger, more mature cardiomyocytes and a marked increase in binucleation
compared to control (Jonker et al., 2010).
Several studies have also shown an increase in cell size of neonatal rat
cardiomyocytes via hypoxia-induced hypertrophy both in vitro (Chu et al., 2012; Ito et
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al., 1996) and in vivo (Radom-Aizik et al., 2013). Furthermore in vitro hypoxia followed
by reoxygenation led to premature senescence and reduced proliferation of neonatal rat
cardiomyocytes (F. X. Zhang et al., 2007). Altogether these studies suggest that hypoxia
stimulates the transition of cardiomyocytes to a terminally differentiated form.
On the contrary, there are a number of studies in support of hypoxia-induced
proliferation of cardiomyocytes. In adult zebrafish, hypoxia induced by ventricular
amputation has been shown to mediate heart regeneration (Jopling, Sune, Faucherre,
Fabregat, & Izpisua Belmonte, 2012), which occurs through the proliferation and
dedifferentiation of cardiomyocytes (Jopling et al., 2010). Furthermore, transgenic mice
overexpressing hypoxia-inducible factor 1alpha (HIF1α) had reduced infarct size and
enhanced cardiac function at 4 weeks after injury with myocardial infarction (Kido et al.,
2005). Additionally, neonatal cardiomyocytes treated with C3orf58, a hypoxia and Akt
induced stem cell factor (HASF) exhibited increased DNA synthesis and number of cells
in mitosis and cytokinesis. Altogether this demonstrates that HASF can induce
proliferation of cardiomyocytes, specifically via the PI3K-AKT-CDK7 pathway (Beigi et
al., 2013). Therefore these studies indicate a possible dual role of hypoxia in regulating
cardiomyocyte proliferation.
Growth restriction in utero can also lead to reduced oxygen supply to the fetus.
Intrauterine growth restriction (IUGR) is associated with hypoxia (Bae et al., 2003;
Moore, 2003; D. Xiao, Ducsay, & Zhang, 2000; L. Zhang, 2005) and has been shown to
reduce the percentage of binucleate cardiomyocytes (Bubb et al., 2007). Furthermore,
Morrison et al. showed that placental restriction leads to chronic fetal hypoxia, which
results in increased percentage of mononucleate cardiomyocytes in the fetal sheep. The
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restricted fetuses have smaller individual cardiomyocytes but when compared relative to
heart weight, the cells were larger (Morrison et al., 2007). The results of this study
suggest that placental restriction-induced hypoxia reduces the total number of
cardiomyocytes in the heart. Other studies demonstrate that after 20 days of
uteroplacental insufficiency, the percentage of binucleate cardiomyocytes as well as cell
cycle activity decreased. In addition, fewer mononucleate cardiomyocytes expressed Ki67, indicating reduced proliferative capacity of these hearts (Louey, Jonker, Giraud, &
Thornburg, 2007).
Therefore studies show support for both a positive and negative effect of hypoxia
on cardiomyocyte proliferation. This could be due to the differences in the age and
species of animal used, as well as methods of hypoxia induction and proliferation
quantification. One possible explanation for hypoxia’s effect on binucleation is that
cardiomyocytes respond by initiating proliferation but are unable to complete cell
division and thus become binucleate. Altogether, studies give evidence that hypoxia is a
major fetal stressor capable of modulating cardiomyocyte endowment in the heart—
ultimately influencing cardiac health throughout life. However the downstream regulators
and molecular mechanism of hypoxia-induced terminal differentiation are not yet known.

Endothelin-1
Endothelins and Endothelin Receptors
Endothelin (ET) is a 21-amino acid peptide involved in regulating vascular
homeostasis. The endothelium-derived peptide was originally isolated from porcine aortic
endothelial cells in 1988 (Yanagisawa, Inoue, et al., 1988). This original peptide was
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identified as endothelin-1 with the subsequent discoveries of two other isoforms,
endothelin-2 (ET-2) and endothelin-3 (ET-3) (Inoue et al., 1989). Endothelin-1 (ET-1) is
currently the most potent vasoconstrictor known (Kawanabe & Nauli, 2011; Yanagisawa,
Inoue, et al., 1988; Yanagisawa, Kurihara, et al., 1988) and is mainly secreted from
vascular endothelial cells (Agapitov & Haynes, 2002). The ET-2 peptide differs from ET1 by two amino acids whereas the ET-3 peptide differs by six amino acids (Kedzierski &
Yanagisawa, 2001).
As shown in Figure 1.2, the endothelin synthesis pathway begins with the
transcription of pre-proendothelin mRNA that is then translated into pre-proendothelin, a
212-residue peptide (Agapitov & Haynes, 2002; Barton & Yanagisawa, 2008). A short
secretary sequence is cleaved before furin-like proteases process the prepro-ET into the
38 to 39-residue peptide, big-endothelin (Agapitov & Haynes, 2002; Barton &
Yanagisawa, 2008). A number of endothelin converting enzyme isoforms (ECE-1, ECE2, ECE-3) cleave the big-ET into the functional 21-residue peptide, endothelin (Agapitov
& Haynes, 2002; Barton & Yanagisawa, 2008; Gao & Raj, 2010). ECE-1 is mainly
found in endothelial cells and ECE-2 is often found in neurons. These two converting
enzymes have a higher affinity for big ET-1 versus big ET-2 or big ET-3 (Kedzierski &
Yanagisawa, 2001). In addition to ECE, it has been shown that chymase and neprilysin
can convert big-ET-1 into its active form ET-1 (Simard et al., 2009). Furthermore, matrix
metalloproteinase-2 (MMP-2, gelatinase A) can also convert human big ET-1 (1-38) to
ET-1 (1-32), which preferentially acts on ETBR (Fernandez-Patron, Radomski, &
Davidge, 1999; Jeyabalan et al., 2003).
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Figure 1.2. Endothelin synthesis and action pathway. Endothelin is mainly secreted by
endothelial cells and can act on either the ETA- or ETB- receptor to elicit a given response.
ET: endothelin; ECE: endothelin-converting enzyme; NOS: nitric oxide synthase; NO:
nitric oxide; ETAR: endothelin A receptor; ETB1R: endothelin receptor B subtype 1; ETB2R:
endothelin receptor B subtype 2.!
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The ET peptides are strong vasoactive substances that can bind one of two types
of G-protein coupled receptors, the ETA- or ETB-receptor. The ETA-receptor (ETAR) is
found in vascular smooth muscle (Hosoda et al., 1991) and therefore associated with the
vasoconstrictor effects of ET. It has the highest binding affinity for ET-1 followed by ET2 and then ET-3 (Arai, Hori, Aramori, Ohkubo, & Nakanishi, 1990; Kawanabe & Nauli,
2011; Sakurai et al., 1990; Yanagisawa, 1994). All three isoforms have equal binding
affinity for the ETB-receptor (ETBR), which is involved in both vasoconstriction and
vasodilatation effects (Arai et al., 1990; Kawanabe & Nauli, 2011; Perreault & Coceani,
2003; Sakurai et al., 1990; Yanagisawa, 1994). Due to the ETBR’s involvement in
constriction and dilatation, it has been categorized into two subtypes, ETB1 and ETB2
(Kedzierski & Yanagisawa, 2001; Warner, Allcock, Corder, & Vane, 1993). The ETB1
subtype is mainly found in endothelial cells (Sakurai et al., 1990) regulating the
vasodilator effect and ETB2 is found predominantly in vascular smooth muscle cells (Arai
et al., 1990) exerting vasoconstrictor effects along with ETAR. The ETBR is also involved
in the clearance of endothelins from tissues (Wilkes, Susin, & Mento, 1993). In
cardiomyocytes, the ETA-receptor is the predominant subtype (Kohan, Rossi, Inscho, &
Pollock, 2011), and has been implicated to play a role in regulating proliferation
(Agapitov & Haynes, 2002; Goldie, 1999; Komuro et al., 1988). In cardiomyocytes, the
ETA-receptor is the predominant subtype (Kohan et al., 2011), and has been implicated to
play a role in regulating proliferation (Agapitov & Haynes, 2002; Goldie, 1999; Komuro
et al., 1988).
The ET-1 peptide is an autocoid (Wilkes et al., 1993) being that it acts in an
autocrine or paracrine fashion rather than as an endocrine (Agapitov & Haynes, 2002;
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Rubanyi & Polokoff, 1994; Wagner et al., 1992). Therefore the local tissue
concentrations are much higher than the low picomolar concentration typically found in
circulation. The endothelial cell is the main site of ET-1 production (Inoue et al., 1989),
but cardiomyocytes are also known to secrete ET-1 (Kedzierski & Yanagisawa, 2001).
ET-2 is secreted in endothelial cells, heart and kidney (Agapitov & Haynes, 2002), while
ET-3 is not produced in endothelial cells (Howard, Plumpton, & Davenport, 1992) but
rather in the endocrine, gastrointestinal, and central nervous systems (Agapitov &
Haynes, 2002). Endothelin is important in normal physiological processes, especially
during growth and development. The general effect of ET is an increase in both blood
pressure and vascular tone (Agapitov & Haynes, 2002; Kelly & Whitworth, 1999), as
well as reducing cardiac output and heart rate (Kelly & Whitworth, 1999). Although
essential to the maintenance of vascular homeostasis, ET-1 can be upregulated in several
pathophysiological conditions, such as hypertension, preeclampsia, and heart failure
(George & Granger, 2011; Rautureau & Schiffrin, 2012; Wei et al., 1994; Zolk et al.,
1999). ET-1 can act as a growth factor and play a key role in tissue development and
differentiation and induce proliferation and vascular smooth muscle cell growth (Goldie,
1999). An upregulation of ET-1 (Ponicke et al., 1998; Zolk et al., 1999) and ETAR and a
downregulation of ETBR were observed in the myocardium of human end-stage heart
failure patients (Zolk et al., 1999). There are many stimuli for the secretion of ET-1
including: vasoactive hormones, growth factors, hypoxia, shear stress, ischemia,
lipoproteins, free radicals, endotoxin and cyclosporine (Gao & Raj, 2010). Endotheliumderived NO, vasodilators, natriuretic peptides, heparin and prostaglandins, can inhibit
ET-1 production (Agapitov & Haynes, 2002).
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Hypoxia Induction of Endothelin-1
Hypoxia is a strong inducer of ET expression via hypoxia-inducible factor 1-alpha
(HIF-1α) (Yamashita, Discher, Hu, Bishopric, & Webster, 2001). HIF-1α is expressed
constitutively but becomes degraded in a normoxic environment. However, in a lowoxygen environment, the enzymes leading to its degradation are inhibited and thus HIF1α can bind to response elements on genes.
The ET-1 gene promoter contains one such hypoxia response element (Hu,
Discher, Bishopric, & Webster, 1998; Kakinuma et al., 2001; Minchenko & Caro, 2000).
Additionally, previous studies demonstrated a negative correlation between pO2 and
plasma ET-1 levels in fetal goats (Yamada et al., 2001) as well as pO2 and ET-1 levels in
human amniotic fluid (Ostlund, Lindholm, Hemsen, & Fried, 2000). ET-1 mRNA levels
were significantly increased in rat lung (H. Li et al., 1994) and placentas (Thaete, Jilling,
Synowiec, Khan, & Neerhof, 2007) exposed to hypoxia. The cardiomyocyte is both a site
of synthesis and action of ET-1 (Kedzierski & Yanagisawa, 2001; Kohan et al., 2011),
suggesting a localized role for hypoxia-induced ET-1 action in the heart.

Central Hypothesis
The central hypothesis of our project is that hypoxia induces ET-1 production,
which stimulates a premature terminal differentiation of cardiomyocytes in the
developing heart via epigenetic modifications.

Significance
It has been well established that an adverse intrauterine environment predisposes
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an individual to an increased risk of cardiovascular disease (Barker & Osmond, 1986;
Bateson et al., 2004; Gluckman, Hanson, Cooper, & Thornburg, 2008). Hypoxia is a
major environmental stress to the developing heart and fetus. A low oxygen environment
is a foremost cause of intrauterine growth restriction (Jensen & Moore, 1997;
McCullough et al., 1977) and poor organ development. The full impact and mechanism
by which hypoxia alters heart development is not yet known. However it is known that
the number of cardiomyocytes endowed in the heart is determined during fetal and
neonatal development. As the heart matures, the cardiomyocytes undergo a terminal
differentiation process and lose their proliferative capacity. Thus the number of
cardiomyocytes in the heart is determined during the first two weeks of neonatal life in
rats (Botting et al., 2012), a number that persists throughout adulthood. Cardiomyocytes
are the functional unit of the heart, and therefore the number of viable myocytes will
dictate cardiac function. By modifying cardiomyocyte endowment via a premature
terminal differentiation, overall cardiac function may be compromised. We expect
findings from our study to reveal a novel role of ET-1 in the hypoxia-induced premature
cardiomyocyte maturation. Moreover, considering the crucial role the intrauterine
environment plays in altering development, the possibility that epigenetic mechanisms
are involved in the premature transition provides a mechanistic understanding worthy of
future investigation.
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Figure 1.3. Proposed model. Proposed sequence of events in which an adverse perinatal environment induces
epigenetic mechanisms, which in turn, alter cardiomyocyte endowment.!

CHAPTER TWO
ENDOTHELIN-1 PROMOTES CARDIOMYOCYTE TERMINAL
DIFFERENTIATION IN THE DEVELOPING HEART VIA HEIGHTENED DNA
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Abstract
Hypoxia is a major stress on fetal development and leads to induction of
endothelin-1 (ET-1) expression. We tested the hypothesis that ET-1 stimulates the
terminal differentiation of cardiomyocytes from mononucleate to binucleate in the
developing heart. Hypoxia (10.5% O2) treatment of pregnant rats from day 15 to day 21
resulted in a significant increase in prepro-ET-1 mRNA expression in fetal hearts. ET-1
ex vivo treatment of fetal rat cardiomyocytes increased percent binucleate cells and
decreased Ki-67 expression, a marker for proliferation, under both control and hypoxic
conditions. Hypoxia alone decreased Ki-67 expression and in conjunction with ET-1
treatment decreased cardiomyocyte size. PD145065, a non-selective ET-receptor
antagonist, blocked the changes in binucleation and proliferation caused by ET-1. DNA
methylation in fetal cardiomyocytes was significantly increased with ET-1 treatment,
which was blocked by 5-aza-2’-deoxycytidine, a DNA methylation inhibitor. In addition,
5-aza-2’-deoxycytidine treatment abrogated the increase in binucleation and decrease in
proliferation induced by ET-1. Hypoxic stress and synthesis of ET-1 increases DNA
methylation and promotes terminal differentiation of cardiomyocytes in the developing
heart. This premature exit of the cell cycle may lead to a reduced cardiomyocyte
endowment in the heart and have a negative impact on cardiac function.

Introduction
Heart disease is the leading cause of death in the United States. It has been well
established that an adverse intrauterine environment increases vulnerability to
cardiovascular disease later in life (Barker, 1995; Barker & Osmond, 1986).
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Environmental factors during the critical period of fetal development can influence the
maturation of organs, such as the heart. Involved in this maturation is a transition of
cardiomyocytes from a mononucleate to a binucleate phenotype. This normal transition
occurs during fetal and early postnatal life, and is attributed to the uncoupling of
cytokinesis from karyokinesis (Clubb & Bishop, 1984). Mononucleate cardiomyocytes
retain the ability to proliferate whereas the binucleate cells do not, and this is because
they have exited the cell cycle and become terminally differentiated (Ahuja, Sdek, et al.,
2007). Alterations to the timing of this critical transition may have long-term
consequences on heart development and function throughout life.
Hypoxia is a major stress to the fetal development. Our previous studies have
shown that an in vivo rat model of maternal hypoxia results in fetal cardiomyocytes
prematurely exiting the cell cycle (Bae et al., 2003; Tong et al., 2013; Tong et al., 2011).
This early-onset transition leads to fewer but larger cardiomyocytes as a result of
increased binucleation and hypertrophy, and decreased proliferation of the cells. The
timing of this transition is critical in determining the number of cardiomyocytes endowed
in the heart for a lifetime. Whereas these in vivo studies showed the effect of hypoxia on
fetal heart development, the mechanisms remain unknown.
Hypoxia is a known inducer of endothelin-1 (ET-1) expression (Hashiguchi et al.,
1991; Ostlund et al., 2000; Yamada et al., 2001; Yamashita et al., 2001). ET-1 plays an
important role in regulating cell cycle, and the cardiomyocyte is both a site of synthesis
and action of ET-1 (Kedzierski & Yanagisawa, 2001; Kohan et al., 2011), suggesting a
localized role for hypoxia-induced ET-1 action in the heart. Thus, the present study tested
the hypothesis that ET-1 induces a premature cardiomyocyte transition in the developing
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heart. Given a recent finding that the terminal differentiation of cardiomyocytes is
characterized by a hypermethylated genome and compact chromatin (Kou et al., 2010),
we further tested the hypothesis that ET-1 promotes cardiomyocyte terminal
differentiation by an increase in DNA methylation. Herein, we present evidence that ET1 via action of ET-1 receptors stimulates the premature transition of fetal
cardiomyocytes, characterized by increased binucleation and decreased proliferation.
DNA methylation of fetal cardiomyocytes is increased with ET-1 treatment, and the ET1-induced changes in binucleation and proliferation are blocked by a DNA methylation
inhibitor 5-aza-2’–deoxycytidine. Altogether the results suggest that epigenetic regulation
via DNA methylation is involved in the cardiomyocyte transition stimulated by increased
synthesis of ET-1.

Materials and Methods
Experimental Animals
Time-dated pregnant Sprague-Dawley rats were purchased from Charles River
Laboratories (Portage, MI) and divided into two groups: (i) normoxic control and (ii)
10.5% O2 hypoxia treatment from gestational day 15 to 21, as previously described
(Patterson, Xiao, Xiong, Dixon, & Zhang, 2012; Xue, Dasgupta, Chen, & Zhang, 2011).
Hearts were isolated from day 21 fetuses. To isolate hearts, pregnant rats were
anesthetized with isoflurane, and adequate anesthesia was determined by loss of pedal
withdrawal reflex. Fetuses were removed and pregnant rats killed by removing the hearts.
Fetal hearts were isolated for the studies. All procedures and protocols were approved by
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the Institutional Animal Care and Use Committee and followed the guidelines by US
National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Primary Cardiomyocyte Culture and Treatment
Cardiomyocytes were isolated from normoxic day 21 fetal rats as previously
described (Y. Xiao, He, Gilbert, & Zhang, 2000). Cells were cultured in Hyclone
Medium 199 (Thermo Scientific) supplemented with 10% fetal bovine serum (Gemini
Bio-Products) and 1% antibiotics (10,000 I.U./mL penicillin, 10,000 µg/mL
streptomycin) at 37°C in 95% air/5% CO2. BrdU (0.1mM) was added to the medium to
prevent fibroblast proliferation. Within three days of culture, the cells formed a
monolayer with synchronized beating, characteristic of viable cardiomyocytes.
Experiments were performed at 70-80% confluency. Cells were treated under normoxia
(21% O2) or hypoxia (1% O2) for 24 hours, in the absence or presence of ET-1 (Sigma;
10 nM), PD145065 (Calbiochem; 10 nM), or 5-aza-2’-deoxycytidine (Sigma; 10 µM).

Real-Time Reverse Transcription-Polymerase Chain Reaction
RNA was isolated from the fetal hearts and prepro-ET-1 mRNA abundance was
determined by real-time RT-PCR using Icycler Thermal cycler (Bio-Rad), as described
previously (Xue et al., 2011). Reverse transcription and cDNA synthesis was performed
using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen). The
primers are 5’-CTAGGTCTAAGCGATCCTTGAA-3’ (forward) and 5’CTTGATGCTGTTGCTGATGG-3’!(reverse). PCR was performed in triplicate, and
threshold cycle numbers were averaged.
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Immunocytochemistry
Primary cardiomyocytes were double stained with alpha-actinin, a cardiomyocyte
marker, and Ki-67, a proliferation marker as described previously (Tong et al., 2013).
Cardiomyocytes were plated on coverslips and fixed with acetone for 10 minutes. The
cells were blocked with 1% bovine serum albumin for 1 hour at room temperature before
incubation with the primary antibodies: mouse anti-α-sarcomeric actinin (Sigma,
St.Louis, MO) (1:200) and rabbit anti-Ki-67 (Abcam, Cambridge, MA) (1:100) in 4°C
overnight. The samples were incubated with the secondary antibodies: anti-mouse FITCconjugated and anti-rabbit Texas Red-conjugated antibodies for 1 hour at room
temperature. Nuclei were stained with Hoescht (Sigma) for 1 minute. The
immunofluorescence staining was assessed using a Zeiss Axio Imager.A1 microscope
and quantitative analysis was carried out using Image J software. Percent binucleation,
Ki-67 expression, and cell size were measured.

5-mC DNA Enzyme-linked Immunosorbent Assay (ELISA)
DNA methylation in primary fetal cardiomyocytes was determined by measuring
5-methylcytosine (5-mC) using a 5-mC DNA ELISA kit (Zymo Research). The kit
features a unique anti-5-mC monoclonal antibody that is both sensitive and specific for 5mC. The protocol for measurement of 5-mC level is described in the manufacturer’s
instruction. Briefly, 100 ng of genomic DNA from cardiomyocytes and standard controls
provided by the kit was denatured and used to coat the plate wells with 5-mC coating
buffer. After incubation at 37°C for 1 hour, the wells were washed with 5-mC ELISA
buffer and then an antibody mix consisting of anti-5-mC and a secondary antibody was
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added to each well. The plate was covered with foil and incubated at 37°C for 1 hour.
After washed out the antibody mix from the wells with 5-mC ELISA buffer, a HRP
developer was added to each well and incubated at room temperature for 1 hour. The
absorbance at 405 nm was measured using an ELISA plate reader. The percent 5-mC was
calculated using the second-order regression equation of the standard curve that was
constructed with negative control and positive controls in the same experiment.

Statistical Analysis
Data are expressed as means ±!SEM. Statistical analysis (p < 0.05) was
determined by analysis of variance followed by Neuman-Keuls post hoc test or Student’s
t test, where appropriate.

Results
Maternal Hypoxia Increased Prepro-ET-1 mRNA in Fetal
Hearts
Animals were exposed to maternal hypoxia from gestational day 15-21; at the end
of treatment hearts were isolated from day 21 fetal rats. Figure 2.1 demonstrated a
significant increase in prepro-ET-1 mRNA abundance in fetal hearts exposed to 10.5%
O2, as compared to the normoxic control (21% O2).
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Figure 2.1. Effect of hypoxia on prepro-ET1 mRNA in the fetal heart. Hearts
were isolated from near-term fetuses of pregnant rats treated with control or
hypoxia. mRNA abundance of prepro-ET-1 was determined by real-time RT-PCR.
Data are means ± SEM. * P < 0.05, hypoxia vs. control. n = 7-8!
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ET-1 Stimulated Binucleation and Inhibited Proliferation of Fetal
Cardiomyocytes
The morphology of mononucleate cells and binucleate cells of primary fetal
cardiomyocytes are shown in Figure 2.2A. Whereas the basal levels of binucleate
cardiomyocytes in fetal hearts were low, the treatment of cardiomyocytes with ET-1
resulted in a significant increase in percent binucleation, as compared to the control in
both normoxic and hypoxic conditions (Figure 2.2A). Hypoxia alone in the absence of
ET-1 had a slight increase in percent binucleation but it did not reach a significant level,
as compared to the normoxic control. Percent Ki-67 positive cells, indicating
proliferation, in ET-1 treated cardiomyocytes were significantly decreased in both
normoxia and hypoxia (Figure 2.2B). Unlike the effect of binucleation, hypoxia alone in
the absence of ET-1 significantly decreased percent of Ki-67 positive cells (Figure 2.2B).
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Figure 2.2. Effect of ET-1 on binucleation and proliferation of fetal
cardiomyocytes. Cardiomyocytes isolated from fetal hearts were treated
with ET-1 (10 nM) under normoxic control (21% O2) or hypoxic (1% O2)
conditions for 24 h. A. Morphology of mononucleate and binucleate fetal
cardiomyocytes. B. Binucleation result. C. Proliferation result. Data are
means ± SEM. * P < 0.05, +ET-1 vs. -ET-1; †!P < 0.05, hypoxia vs. control.
n = 5!
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Interaction of ET-1 and Hypoxia Decreased Cardiomyocyte Size
Neither ET-1 nor hypoxia alone had a significant effect on cardiomyocyte size
(Figure 2.3). However, cardiomyocyte size was significantly decreased with the ET-1
treatment under the hypoxic condition (Figure 2.3).
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Figure 2.3. Effect of ET-1 on fetal cardiomyocyte size. Cardiomyocytes
isolated from fetal hearts were treated with ET-1 (10 nM) under normoxic
control (21% O2) or hypoxic (1% O2) conditions for 24 h. Data are means ±
SEM. * P < 0.05, +ET-1 vs. -ET-1. n = 7-10!
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PD145065 Inhibited the Effects of ET-1
PD145065, a non-selective ET-receptor antagonist, blocked the effects of ET-1 on
percent binucleation (Figure 2.4A) and Ki-67 expression (Figure 2.4B) in fetal
cardiomyocytes. PD145065 in the absence of ET-1 had no significant effect on either
binucleation or proliferation of cardiomyocytes.
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Figure 2.4. PD145065 abrogates ET-1-mediated effects on binucleation
and proliferation of fetal cardiomyocytes. Cardiomyocytes isolated from
fetal hearts were treated with ET-1 (10 nM) for 24 h in the absence or
presence of PD145065 (10 nM). A. Binucleation result. B. Proliferation
result. * P < 0.05, ET-1 vs. control. n = 5!
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ET-1 Increased DNA Methylation in Fetal Cardiomyocytes
ET-1 treatment of fetal cardiomyocytes resulted in a significant increase in DNA
methylation, seen as increased percent 5-mC in Figure 2.5. In the presence of 5-aza-2’deoxycytidine, a DNA methylation inhibitor, the effects of ET-1 were blocked (Figure
2.5).
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Figure 2.5. 5-Aza-2’-deoxycytidine blocks ET-1-increased DNA methylation in
fetal cardiomyocytes. Cardiomyocytes isolated from fetal hearts were treated with
ET-1 (10 nM) for 24 h in the absence or presence of 5-aza-2’-deoxycytidine (5-Aza,
10 µM). * P < 0.05, ET-1 vs. control. n = 5!
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5-Aza-2’-deoxycytidine Abrogated the Effects of ET-1 on Fetal
Cardiomyocytes
In the presence of 5-aza-2’-deoxycytidine, ET-1-induced stimulation of
binucleation (Figure 2.6A) and inhibition of Ki-67 expression (Figure 2.6B) in fetal
cardiomyocytes were blocked. Whereas 5-aza-2’-deoxycytidine alone in the absence of
ET-1 had a tendency to increase cardiomyocyte binucleation, this effect did not reach the
significant level (Figure 2.6A).
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Figure 2.6. 5-Aza-2’-deoxycytidine abrogates ET-1-mediated effects on
binucleation and proliferation of fetal cardiomyocytes. Cardiomyocytes
isolated from fetal hearts were treated with ET-1 (10 nM) for 24 h in the
absence or presence of 5-aza-2’-deoxycytidine (5-Aza, 10 µM). A. Binucleation
result. B. Proliferation result. * P < 0.05, ET-1 vs. control. n = 5!
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Discussion
The present study provides evidence that ET-1 inhibited proliferation and induced
the premature transition of fetal cardiomyocytes from a mononucleate to a binucleate
phenotype, indicative of terminally differentiated cardiomyocytes. Hypoxia alone did not
elicit the same effects as ET-1. An ET-receptor antagonist, PD145065 blocked the ET-1induced increase in binucleation and decrease in proliferation. Additionally, we
demonstrated that ET-1 treatment increased DNA methylation in fetal cardiomyocytes,
and a DNA methylation inhibitor, 5-aza-2’-deoxycytidine abrogated ET-1-induced DNA
methylation and terminal differentiation of cardiomyocytes.
The ET-1 synthesis pathway begins with the transcription of prepro-ET-1 mRNA,
which is translated into prepro-ET-1. A series of enzymatic cleavages produce Big-ET-1
and the matured ET-1, a 21-amino acid peptide (Barton & Yanagisawa, 2008). Several
studies have reported the regulation of ET-1 synthesis by hypoxia, including the
identification of a HIF-1 binding site on the prepro-ET-1 gene promoter (Hu et al., 1998;
Minchenko & Caro, 2000). Specifically in cardiomyocytes, a HIF-1α!binding site has
been identified on the 5’-promoter region of the prepro-ET-1 gene (Kakinuma et al.,
2001). Additionally, previous studies demonstrated a negative correlation between pO2
and plasma ET-1 levels in fetal goats (Yamada et al., 2001) as well as pO2 and ET-1
levels in human amniotic fluid (Ostlund et al., 2000). ET-1 mRNA levels were
significantly increased in rat lung (H. Li et al., 1994) and placentas (Thaete et al., 2007)
exposed to hypoxia. In agreement with these findings, the present study demonstrated a
significant increase in prepro-ET-1 mRNA in the fetal rat heart resulting from in utero
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hypoxia, suggesting a local paracrine action of ET-1 in hypoxia-mediated effect on the
fetal heart.
Physiological circulating levels of ET-1 are in the low picomolar range (Kohan et
al., 2011; Nakas-Icindic, Zaciragic, Hadzovic, & Avdagic, 2004) and may be
significantly upregulated in pathophysiological conditions, such as hypoxia, heart failure,
hypertension, and preeclampsia (George & Granger, 2011; Rautureau & Schiffrin, 2012;
Wei et al., 1994; Zolk et al., 1999). ET-1 acts in a paracrine and/or autocrine fashion and
therefore tissue concentrations are significantly higher than those in the circulation
(Rubanyi & Polokoff, 1994). The concentration of ET-1 (10 nM) was chosen based on
other studies (Ito et al., 1991; X. Li et al., 2009; Majumdar et al., 2009; Yu et al., 2013)
and the rationale that ET-1 levels in the local tissue are much greater than in circulation.
In the present study, we found that fetal rat cardiomyocytes exposed to elevated levels of
ET-1 exhibited both increased binucleation and decreased proliferation. The binucleate
cells are unable to proliferate and thus become terminally differentiated. In the rat heart,
normal transition of cardiomyocytes to the binucleate form starts at birth and lasts during
the first two weeks of postnatal life (Clubb & Bishop, 1984). Therefore, the accelerated
transition in the fetal heart due to increased levels of ET-1 has long-term implications. A
premature transition of terminal differentiation may result in a reduced number of
cardiomyocytes and altered cardiac growth after birth. As previous work has shown,
hypoxia causes a premature exit of cell cycle in fetal cardiomyocytes (Bae et al., 2003),
but the downstream regulators are not known.
The present study demonstrated that ET-1 increased the percent of binucleate
cells independent of hypoxia, and hypoxia alone had no significant effect on the
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binucleation of cardiomyocytes. These findings suggest a lack of direct effect of hypoxia
on the cardiomyocyte transition and provide evidence that ET-1 is a key downstream
regulator of the premature exit of cell cycle in the fetal heart, observed in vivo in fetal
hypoxia (Bae et al., 2003). It is important to note that while cardiomyocytes have the
ability to produce ET-1, endothelial cells contribute a large portion of its production. The
isolated cardiomyocytes may not provide the full mechanism for hypoxia to produce a
sufficient ET-1 response and the subsequent effects on binucleation and cell size. The
finding that PD145065 blocked the ET-1-induced increase in binucleation and decrease
in proliferation of fetal cardiomyocytes indicates the ET-1 receptor-mediated effects.
PD145065 is a non-selective ETA- and ETB-receptor antagonist and has been shown to
block the effect of ET-1 via the ET-receptors (Ceccarelli et al., 2003; Doherty et al.,
1993; Drimal et al., 2003).
The finding that hypoxia decreased proliferation of fetal cardiomyocytes is in
agreement with previous reports (Bae et al., 2003; Tong et al., 2013; Tong et al., 2011).
Prior studies have shown that hypoxia promotes HIF-1α!association with HIF-1β!and
enhances the expression of cyclin-dependent kinase inhibitors (CKIs), which in turn
inhibits cell cycle proteins and decreases cell proliferation (Goda, Ryan, et al., 2003). It is
also suggested that HIF-1 regulates the G1/S phase transition by regulating the expression
of cyclin E, a required factor for the transition (Goda, Dozier, & Johnson, 2003). Hypoxia
has also been shown to induce expression of metalloproteinase inhibitors (TIMPs) that
may have an inhibitory or stimulatory effect on cellular proliferation depending on the
subtype and tissue involved (Tong & Zhang, 2012). In the heart, TIMP-3 is highly
expressed and shown to inhibit proliferation in neonatal mouse cardiomyocytes
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(Hammoud et al., 2007); a result of up-regulated p27 expression via the EGFR-JNK-SP-1
mediated pathway (Hammoud, Burger, Lu, & Feng, 2009). Although TIMP-3 and -4 are
upregulated by hypoxia, their promoters do not contain HIF-responsive elements. Thus
the regulation of these inhibitors and the subsequent effects on proliferation appear to be
mediated by other genes that contain HIF-responsive elements.
ET-1 is one possible candidate considering it both contains a HIF-response
element in its promoter (Hu et al., 1998; Minchenko & Caro, 2000) and has been shown
to regulate proliferation (Bae et al., 2003; Tong et al., 2013; Tong et al., 2011; F. X.
Zhang et al., 2007). The finding that, unlike ET-1, hypoxia had no significant effect on
binucleation suggests that hypoxia-induced effect on proliferation was not mediated by
ET-1, but rather by an independent and direct effect of hypoxia. The synergistic effect of
hypoxia and ET-1 more closely mimics the physiological system as a whole. Ki-67
expression and cell size were significantly decreased by hypoxia and ET-1 treatment
together. These results agree with previous reports, from our lab and others, that hypoxia
alone had a direct effect in decreasing proliferation of cardiomyocytes (Bae et al., 2003;
Tong et al., 2013; Tong et al., 2011; F. X. Zhang et al., 2007).
A change in cell size was only observed with the addition of both ET-1 and
hypoxia. Both ET-1 and hypoxia are known hypertrophic factors (Ito et al., 1996;
Shubeita et al., 1990; Suzuki, Hoshi, & Mitsui, 1990). In neonatal rat cardiomyocytes,
mild hypoxia (10% O2) has been found to induce hypertrophy (Chu et al., 2012; Ito et al.,
1996). However more severe hypoxia (1% O2), as was done in our study, appears to elicit
the opposite effect leading to a reduction in cell size. Thus the severity at which hypoxia
is induced likely has a differential effect on changes in cellular size. ET-1 has also been
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shown to stimulate cardiomyocytes to proliferate, and in the case of terminally
differentiated cells it leads to hypertrophy (Cullingford et al., 2008; Ito et al., 1991).
Furthermore previous studies have found that hypertrophic growth is initially observed in
the first week of postnatal life (Clubb & Bishop, 1984; F. Li et al., 1996). Given that fetal
and neonatal hearts are at very different developmental stages and experience very
different oxygen tensions, it is possible that cardiomyocytes of the fetal heart respond
differently to environmental cues such as hypoxia as that seen in the neonatal
cardiomyocytes.
The finding that 5-aza-2’-deoxycytidine blocked the ET-1-induced increase in
binucleation and decrease in proliferation is intriguing and suggests that ET-1 induces
methylation of DNA as a means of involvement in cardiomyocyte terminal differentiation
and suppression of proliferation. Whereas the present study focused on the downstream
mechanisms of ET-1 in regulating terminal differentiation of cardiomyocytes, whether
DNA methylation plays a role in the hypoxia-mediated direct effect on proliferation
remains to be determined. 5-Aza-2’-deoxycytidine has been widely used as a DNA
methylation inhibitor, and in the concentration range of 1 to 30 µM it inhibits DNA
methylation both globally and at specific sites of DNA (Meyer, Zhang, & Zhang, 2009;
Patterson et al., 2010; Vallender & Lahn, 2006; F. Xiong, Xiao, & Zhang, 2012). In the
present study, we found that ET-1 significantly increased global DNA methylation in
cardiomyocytes and this was blocked by 5-aza-2’-deoxycytidine. Epigenetic mechanism
of DNA methylation acts to silence gene transcription, typically at cytosine residues
within CpG dinucleotides. A previous study showed that methylation gradually increases
over the course of development in neonatal cardiomyocytes (Kou et al., 2010), the same
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time frame for which binucleation occurs. Furthermore, expression of DNA
methyltransferases involved in de novo DNA methylation (DNMT3a and DNMT3b) was
significantly increased during the first 90 days of postnatal life. Inhibition of methylation
with 5-aza-2’-deoxycytidine during neonatal day 7 and 10 resulted in a marked increase
in DNA synthesis and delayed maturation (Kou et al., 2010). It is well known that
environmental cues during fetal development can profoundly alter the structure and
function of an organ via epigenetic regulation. Particularly in the heart, cardiac function
is dependent in part on cardiomyocyte number. Thus hypoxia-mediated ET-1 may signal
through epigenetic mechanisms to negatively impact cardiomyocyte development. The
present study suggests that DNA methylation is an epigenetic mechanism through which
ET-1 stimulates cardiomyocyte transition of terminal differentiation. Ultimately, this may
lead to reduced total cardiomyocyte number in the heart. Many studies have
demonstrated that genes associated with the cell cycle and cytokinesis are involved in this
transition process (Ahuja, Perriard, et al., 2007; Chen et al., 2004; Engel, Schebesta, &
Keating, 2006; Y. Liu et al., 2007; Sdek et al., 2011). Adult cardiomyocytes from
knockout mice lacking Rb and p130 show a decrease in heterochromatin and an increase
in proliferation associated with derepression of cell cycle genes (Sdek et al., 2011). These
genes may be differentially regulated by changes in methylation patterns thus altering the
cell cycle and cytokinesis. Future studies will have to elucidate the methylation status of
specific genes during this transition phase.
The present study identifies a novel mechanism of ET-1-induced
hypermethylation as a downstream regulator of hypoxia-mediated cardiomyocyte
transition from mononucleate to binucleate cells in the developing heart. Cardiomyocyte
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endowment is determined during fetal and early postnatal development, when most
cardiomyocytes become binucleate and cease to proliferate (Botting et al., 2012;
Thornburg et al., 2011). Given that hypoxia is one of the most important and clinically
relevant stresses to the fetal development, and that fetal hypoxia results in fewer but
larger cardiomyocytes and increases the susceptibility of heart to ischemic injury in
offspring (Bae et al., 2003; G. Li, Bae, & Zhang, 2004; G. Li et al., 2003; Xu, Williams,
O'Brien, & Davidge, 2006), the present study provides a mechanistic understanding
worthy of further investigation in humans.

Acknowledgements
A portion of this research used the Loma Linda University School of Medicine
Advanced Imaging and Microscopy Core, a facility supported in part by the National
Science Foundation through the Major Research Instrumentation program of the Division
of Biological Infrastructure Grant No. 0923559 and the Loma Linda University School of
Medicine.

46!

CHAPTER THREE
NEWBORN HYPOXIA/ANOXIA INHIBITS CARDIOMYOCYTE
PROLIFERATION AND DECREASES ENDOWMENT IN THE DEVELOPING
HEART: ROLE OF ENDOTHELIN-1

By
Alexandra Paradis, Maresha Gay, Christopher Wilson, and Lubo Zhang

This paper has been published by PLoS One. 2015 Feb 18;10(2):e0116600

47!

Abstract
In the developing heart, cardiomyocytes undergo terminal differentiation during a
critical window around birth. Hypoxia is a major stress to preterm infants, yet its effect
on the development and maturation of the heart remains unknown. We tested the
hypothesis in a rat model that newborn anoxia accelerates cardiomyocyte terminal
differentiation and results in reduced cardiomyocyte endowment in the developing heart
via an endothelin-1-dependent mechanism. Newborn rats were exposed to anoxia twice
daily from postnatal day 1 to 3, and hearts were isolated and studied at postnatal day 4
(P4), 7 (P7), and 14 (P14). Anoxia significantly increased HIF-1α protein expression and
pre-proET-1 mRNA abundance in P4 neonatal hearts. Cardiomyocyte proliferation was
significantly decreased by anoxia in P4 and P7, resulting in a significant reduction of
cardiomyocyte number per heart weight in the P14 neonates. Furthermore, the expression
of cyclin D2 was significantly decreased due to anoxia, while p27 expression was
increased. Anoxia has no significant effect on cardiomyocyte binucleation or myocyte
size. Consistently, prenatal hypoxia significantly decreased cardiomyocyte proliferation
but had no effect on binucleation in the fetal heart. Newborn administration of
PD156707, an ETA-receptor antagonist, significantly increased cardiomyocyte
proliferation at P4 and cell size at P7, resulting in an increase in the heart to body weight
ratio in P7 neonates. In addition, PD156707 abrogated the anoxia-mediated effects. The
results suggest that hypoxia and anoxia via activation of endothelin-1 at the critical
window of heart development inhibits cardiomyocyte proliferation and decreases
myocyte endowment in the developing heart, which may negatively impact cardiac
function later in life.
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Introduction
The intrauterine environment plays a well-established role in predisposition to
cardiovascular disease later in life (Barker, 1995). Environmental factors during the
critical period of heart development may alter the maturation of the heart and thus
potentially its life-long function. Cardiomyocytes are the functional contractile units of
the heart that undergo a normal maturation process in which terminal differentiation is
the final outcome. As the cardiomyocytes terminally differentiate and exit the cell cycle,
they lose their proliferative capacity (Ahuja, Sdek, et al., 2007). Cardiomyocyte growth
then transitions from hyperplastic to hypertrophic, in which the cells can only increase in
size rather than number (Bugaisky & Zak, 1979; F. Li et al., 1996). Ultimately the
proliferative capacity of cardiomyocytes is lost and the adult heart is known to exhibit
negligible increases in cell number (Bergmann et al., 2009). Therefore the timing of this
transition is pivotal in determining cardiomyocyte endowment in the heart for the rest of
the animal’s life.
Hypoxia is a major stress to preterm infants, yet its effect on the development and
maturation of the heart remains unknown. Given that the transition of cardiomyocyte
terminal differentiation occurs in rodents during the first two weeks of neonatal life
(Clubb & Bishop, 1984; F. Li et al., 1996), which is an equivalent timeframe to the late
fetal stage in third trimester of human gestation (Ahuja, Sdek, et al., 2007), they provide a
reasonable animal model to study the effect of anoxia on preterm infants at the critical
window of the heart development. This process of terminal differentiation begins in the
rat heart around postnatal day 4 (F. Li et al., 1996) and progresses until day 14 when the
heart is essentially mature, thus three time-points within this period were evaluated in this
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study. Previous studies in rats have shown that maternal hypoxia (10.5 % O2) leads to a
premature exit from the cell cycle in fetal cardiomyocytes (Bae et al., 2003; Tong et al.,
2013; Tong et al., 2011). Additionally, neonatal cardiomyocytes have been shown to
decrease proliferation when exposed to hypoxic conditions (F. X. Zhang et al., 2007).
Studies have also been performed in sheep in which placental restriction is induced,
resulting in reduced cardiomyocyte maturation (Bubb et al., 2007) and proliferation
(Louey et al., 2007), increased proportion of mononucleate cardiomyocytes (Morrison et
al., 2007), and decreased cardiomyocyte endowment (Botting et al., 2014). However, the
in vivo effects of anoxia, as a preterm model, on cardiomyocyte proliferation and
endowment in the developing rat heart are, as of yet, not known. Additionally, the
downstream regulators of cardiomyocyte proliferation and maturation are unknown.
Endothelin-1 (ET-1) expression is induced by hypoxia (Hashiguchi et al., 1991;
Ostlund et al., 2000; Yamada et al., 2001; Yamashita et al., 2001). Studies performed in
endothelial cells (Hu et al., 1998; Minchenko & Caro, 2000) and cardiomyocytes
(Kakinuma et al., 2001) have identified a HIF-1α binding site in the prepro-ET-1 gene.
Furthermore, the cardiomyocyte is both a site of synthesis and action for ET-1
(Kedzierski & Yanagisawa, 2001; Kohan et al., 2011), as it acts mainly at the paracrine
or autocrine level (Agapitov & Haynes, 2002; Rubanyi & Polokoff, 1994). Our recent
work showed that ex vivo ET-1 treatment promoted terminal differentiation of fetal
cardiomyocytes, via an increase in DNA methylation (Paradis, Xiao, Zhou, & Zhang,
2014). The predominant ET-1 receptor subtype in cardiomyocytes is the ETA-receptor
(Kohan et al., 2011), which is thought to be involved in regulating proliferation
(Agapitov & Haynes, 2002; Goldie, 1999; Komuro et al., 1988). Currently, little is
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known about the role that basal ET-1 plays in the terminal differentiation of
cardiomyocytes, as well as the effect of hypoxia/anoxia-induced ET-1 production on this
process.
Therefore, in the present study we tested the hypothesis that in vivo neonatal
anoxia decreases proliferation of cardiomyocytes via the ETA-receptor-dependent
mechanisms, resulting in reduced cardiomyocyte endowment in the developing heart.
Herein, we provide evidence that the ETA-receptor mediates the anoxia-induced decrease
in cardiomyocyte proliferation. Furthermore, cardiomyocyte endowment in the
developing heart was decreased by anoxia and restored with PD156707, a selective ETAreceptor antagonist.

Methods
Experimental Animals
Time-dated pregnant Sprague-Dawley rats were purchased from Charles River
Laboratories (Portage, MI) and allowed to give birth. Neonatal pups from 7 litters were
used and divided into the treatment groups. Data from pups of multiple litters were
pooled. Starting at postnatal day 1, newborn rats were placed in a temperature-controlled
(37˚C) anoxia chamber. Nitrogen was infused into the chamber for 10 minutes and an
oxygen sensor was used to verify the level of oxygen in the chamber being < 0.2%.
Control animals were placed in a chamber with oxygen maintained at 21%. Anoxia
treatments were performed twice a day with 8 hours in between, from postnatal day 1
until postnatal day 3. A group of animals was treated with intraperitoneal injections of an
ETA-receptor antagonist, PD156707 (2 mg/kg), prior to each episode of anoxia, twice a
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day for the first 3 postnatal days. Neonatal pups were anesthetized with isoflurane and
hearts isolated for studies on postnatal day 4, 7, and 14. To investigate the comparative
effect of prenatal hypoxia, some of the time-dated pregnant Sprague-Dawley rats were
treated with either normoxic control or 10.5% O2 from gestational day 15 to 21, as
previously described (Patterson et al., 2012; Xue et al., 2011). Following the hypoxia
treatment, pregnant rats were allowed to give birth. Hearts were isolated from postnatal
day 4 and 7 neonatal rats. All procedures and protocols were approved by the Loma
Linda University Institutional Animal Care and Use Committee (IACUC) and all
procedure adhered to the guidelines by US National Institutes of Health Guide for the
Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/Guide-for-thecare-and-use-of-laboratory-animals.pdf).

Measurement of Cardiomyocyte Number
Hearts from day 4, 7, and 14 neonatal pups were isolated and the atria excised.
The hearts were then completely enzymatically digested to yield primary
cardiomyocytes, as previously described (Paradis et al., 2014; Y. Xiao et al., 2000). A
pre-plate step was performed to enrich the cardiomyocyte population. This is a
commonly used method (Chlopcikova, Psotova, & Miketova, 2001) that is based on the
differential attachment of cardiomyocytes and non-myocyte cells of the heart.
Cardiomyocytes take approximately 24 hours to fully attach to the plate while nonmyocytes attach within a couple hours. After a 2-hour pre-plate step to remove attached
non-myocytes, cardiomyocytes in the media were collected and used for counting
cardiomyocyte number via hemacytometer. Briefly, an aliquot of cardiomyocytes was
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counted using a hemacytometer and the counts were multiplied by the total volume of
cell suspension and normalized according to the heart weight, to yield the number of
cardiomyocytes per heart weight.

Immunocytochemistry
To perform immunocytochemical staining, cardiomyocytes isolated from day 4
and 7 hearts were allowed to attach to plates in Hyclone Medium 199 (Thermo Scientific)
supplemented with 10% fetal bovine serum (Gemini Bio-Products) and 1% antibiotics
(10,000 I.U./mL penicillin, 10,000 µg/mL streptomycin) at 37°C in 95% air/5% CO2.
After 24 hours, cardiomyocytes were fully attached and were double stained with alphaactinin, a cardiomyocyte marker, and Ki-67, a proliferation marker as described
previously (Paradis et al., 2014; Tong et al., 2013). Cardiomyocytes were plated on
coverslips and fixed with 4% paraformaldehyde (ThermoScientific) for 15 minutes
followed by permeabilization with Triton X-100 (Fisher) for 10 minutes. The cells were
blocked with 1% bovine serum albumin for 1 hour at room temperature before incubation
with the primary antibodies: mouse anti-α-sarcomeric actinin (A7811, Sigma) (1:200)
and rabbit anti-Ki-67 (ab16667, Abcam) (1:100) at room temperature for 1 hour. The
samples were incubated with the secondary antibodies: anti-mouse Alexa Fluor 488
(A21202, Life Technologies) and anti-rabbit Alexa Fluor 647 antibodies (A21244, Life
Technologies) for 1 hour at room temperature. Nuclei were stained with Hoescht (Sigma)
for less than 1 minute. The immunofluorescence staining was assessed using a Zeiss Axio
Imager.A1 microscope and quantitative analysis was carried out using ImageJ software
(http://imagej.nih.gov/ij/). Ki-67 expression, binucleation, and cell size were measured.
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Flow Cytometry
Primary cardiomyocytes isolated from day 14 neonatal rats were stained for
analysis by flow cytometry. Cells were washed in staining buffer (PBS + 5% FBS), spun
down, and re-suspended in 4% paraformaldehyde for 20 minutes at room temperature in
the dark. The fixed cells were then washed in permeabilization wash buffer (eBioscience)
and supernatant discarded. Cells were stained with antibodies for the cardiomyocyte
marker, Troponin T (ab10214, Abcam) (1:200), and proliferation marker, Ki-67conjugated to allophycocyanin (APC) (eBioscience) (50-5698, 1:200). After incubation
and washing, cells were incubated with the secondary antibody for Troponin T,
fluorescein isothiocyanate (FITC) (555988, BD Pharmingen) (1:100). Finally cells were
washed and resuspended in 1% paraformaldehyde to be run on a FACSAria (BD
Biosciences) and analyzed via FACSDiva software (BD Biosciences) for percentage of
Ki-67 expressing cardiomyocytes.

Real-Time Reverse Transcription-Polymerase Chain Reaction
RNA was isolated from the postnatal day 4 (P4) hearts and prepro-ET-1 mRNA
abundance was determined by real-time RT-PCR using Icycler Thermal cycler (BioRad), as described previously (Xue et al., 2011). Reverse transcription and cDNA
synthesis was performed using SuperScript III First-Strand Synthesis Supermix for RTPCR (Life Technologies). The primers are 5’-CTAGGTCTAAGCGATCCTTGAA-3’
(forward) and 5’-CTTGATGCTGTTGCTGATGG-3’!(reverse). PCR was performed in
triplicate, and threshold cycle numbers were averaged.
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Western Immunoblotting
HIF-1α, ETA-receptor (ETAR), and ETB-receptor (ETBR) protein abundance in the
P4 heart was measured from control and anoxia groups. The protein abundance of cyclin
D2 and p27 was measured in P4 hearts from control and anoxia groups as well as in the
presence and absence of PD156707. Tissues were homogenized and protein isolated
using the RIPA lysis buffer system (Santa Cruz Biotechnology). Protein concentrations
were quantified using the BCA protein assay (ThermoScientific) and all samples were
loaded with equal protein onto 7.5% (HIF-1α) or 10% (ETAR, and ETBR, cyclin D2, and
p27) polyacrylamide gel with 0.1% sodium dodecyl sulfate (SDS). Proteins were then
separated by electrophoresis and transferred onto nitrocellulose membranes. Non-specific
binding sites were blocked with Tris-buffered saline solution (TBS) containing 5% dry
milk. The membranes were incubated with primary antibodies against HIF-1α!(sc10790,
Santa Cruz Biotechnology; 1:500), ETAR (sc33536, Santa Cruz Biotechnology; 1:500),
ETBR (sc33538, Santa Cruz Biotechnology; 1:500), cyclin D2 (ab3085, Abcam; 1:1000),
and p27 (ab7961, Abcam; 1:1000). After washing, membranes were incubated with
secondary antibodies. Proteins were visualized with enhanced chemiluminescence
reagents and western blots were exposed to Hyper film. Kodak image software was used
to quantify all results.

Statistical Analysis
Data are expressed as means ±!SEM. Statistical analysis (p < 0.05) was
determined by two-way analysis of variance (ANOVA) followed by Neuman-Keuls post
hoc test or Student’s t test, where appropriate, using GraphPad Prism software. The two-
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way ANOVA was performed to evaluate the effects of two factors, within each age
group: (1) control versus anoxia, and (2) in the presence and absence of PD156707.

Results
Newborn Anoxia Treatment Increased Pre-proET-1 mRNA in the Heart
Neonatal rats were exposed to anoxia twice a day from postnatal day 1 to 3, and
hearts were isolated at P4. As seen in Figure 3.1, there was a significant increase in
prepro-ET-1 mRNA abundance in neonatal hearts exposed to anoxia (< 0.2% O2), as
compared to the normoxic control (21% O2).
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Figure 3.1. Effect of newborn anoxia on prepro-ET-1 mRNA in the neonatal
heart. Hearts were isolated from day 4 neonatal rats treated with control or anoxia.
mRNA abundance of prepro-ET-1 was determined by real-time RT-PCR. Data are
means ± SEM. * P < 0.05, anoxia vs. control. n = 3–5!
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Newborn Anoxia Treatment Increased HIF-1α Protein Abundance in
the Heart
Hearts from P4 rats treated with anoxia were collected and protein isolated.
Neonatal hearts exposed to anoxia had significantly increased levels of the HIF-1α
protein (Figure 3.2).
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Figure 3.2. Effect of newborn anoxia on HIF-1〈 protein abundance in the
neonatal heart. Hearts were isolated from day 4 neonatal rats treated with
control or anoxia. Protein abundance of HIF-1〈 was determined by Western
immunoblotting. Data are means ± SEM. * P < 0.05, anoxia vs. control. n = 4!
!
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Newborn Anoxia Treatment Decreased Cardiomyocyte Proliferation
As shown in Figure 3.3, there is a development-dependent decrease in
cardiomyocyte proliferation at the critical window of the heart development during the
first two weeks of life in rodents, and myocyte proliferation reduces to minimal levels at
postnatal day 14. Anoxia treatment of newborns caused a significant decrease in the
proliferation of neonatal cardiomyocytes at both postnatal days 4 and 7 (Figure 3.3B).
Treatment of newborn rats with a selective ETA-receptor antagonist, PD156707, caused a
significant increase in cardiomyocyte proliferation in P4 neonatal rats (Figure 3.3B). In
addition, PD156707 abrogated the anoxia-induced effects in the developing hearts
(Figure 3.3B). In contrast to proliferation, there is a development-dependent increase in
cardiomyocyte binucleation in the developing heart (Figure 3.3C). Neither anoxia nor
PD156707 treatments had significant effects on cardiomyocyte binucleation (Figure
3.3C).
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Figure 3.3. Effect of newborn anoxia and PD156707 on proliferation and
binucleation of neonatal cardiomyocytes. Cardiomyocytes were isolated from P4,
P7, and P14 neonatal rats that were treated with control or anoxia, in the absence or
presence of PD156707. Cells from P4 and P7 rats were stained with α-actinin and
Ki-67, and nuclei were stained using Hoechst staining. P14 cardiomyocytes were
stained with Ki-67 and analyzed via FACS. Panel A shows a representative image
of cardiomyocytes stained with alpha-actinin (green), Ki-67 (red), and Hoescht
(blue). Panel B shows percent of Ki-67 expressing cells. Panel C shows percent of
binucleate cells. Data are means ± SEM. * P < 0.05, anoxia vs. control. †!P < 0.05, PD156707 vs. +PD156707. PD: PD156707; n: animal numbers.!
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Newborn Anoxia Treatment Decreased Cyclin D2 and Increased p27
Expression
The protein expression of cyclin D2 was decreased due to anoxia treatment and
this effect was abolished in the presence of PD156707 (Figure 3.4A). On the contrary,
p27 expression in the neonatal heart was significantly increased due to anoxia treatment,
and PD156707 blocked the effect of anoxia (Figure 3.4B).
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Figure 3.4. Effect of newborn anoxia on cyclin D2 and p27 protein
expression in the cardiomyocyte. Hearts were isolated from day 4 neonatal
rats treated with control or anoxia in the presence (n = 6-7) or absence (n = 4) of
PD156707. Protein abundance of cyclin D2 in the absence and presence of
PD156707 (A), and p27 in the absence and presence of PD156707 (B) was
determined by Western immunoblotting. Data are means ± SEM. * P < 0.05,
anoxia vs. control.!
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Newborn Anoxia Treatment Decreased Cardiomyocyte Number
by Day 14
There was no significant change in cardiomyocyte number due to newborn anoxia
treatment at day 4 and 7. However, results for day 14 show that anoxia leads to a
significant decrease in cardiomyocyte number per heart weight (Figure 3.5). PD156707
alone caused a significant increase in cardiomyocyte number in the day 7 neonate (Figure
3.5). In the presence of PD156707, the anoxia-mediated effects at day 14 were blocked
(Figure 3.5).
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Figure 3.5. Effect of newborn anoxia and PD156707 on number of
cardiomyocytes per heart weight. Cardiomyocytes were isolated from day 4, 7, and
14 neonatal rats that were treated with control or anoxia, in the absence or presence of
PD156707. Hearts were weighed and cardiomyocytes counted by hemacytometer
(day 4 and 7) and FACS (day 14). Data are expressed as cardiomyocyte number/g
heart weight, and are means ± SEM. * P < 0.05, anoxia vs. control. †! P < 0.05, PD156707 vs. +PD156707. PD: PD156707; n: animal numbers.!
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Cell Size was Increased in the Presence of PD156707
Anoxia had no effect on mononucleate or binucleate cell size at both day 4 and 7
(Figure 3.6). However, PD156707 treatment was able to increase both mononucleate and
binucleate cell size at postnatal day 7 (Figure 3.6).
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Figure 3.6. Effect of newborn anoxia and PD156707 on cardiomyocyte size in
the neonatal heart. Cardiomyocytes were isolated from day 4, 7, and 14 neonatal
rats that were treated with control or anoxia, in the absence or presence of
PD156707. Mononucleate (A) and binucleate (B) cell size was measured using
ImageJ. Data are means ± SEM. †! P < 0.05, -PD156707 vs. +PD156707. PD:
PD156707; n: animal numbers.!
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PD156707 Increased Heart to Body Weight Ratio
There was no significant effect of anoxia on the heart to body weight ratio for any
day (Figure 3.7). However, PD156707 treatment significantly increased the heart to body
weight ratio in day 4 and 7 neonates (Figure 3.7). Heart and body weight averages in the
presence and absence of anoxia and PD156707 are listed in Table 3.1.
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Figure 3.7. Effect of newborn anoxia and PD156707 on heart to body weight
ratio of neonatal rats. Body and heart weights were taken from day 4, 7, and 14
neonatal rats that were treated with control or anoxia, in the absence or presence of
PD156707. Data are means ± SEM. †!P < 0.05, -PD156707 vs. +PD156707. PD:
PD156707; n: animal numbers.!
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+PD156707

-PD156707

!

P7
14.44 ±
0.550 (8)
13.65 ±
0.472 (12)
15.05 ±
0.289 (6)
12.75 ±
0.302 (7)

P4
8.51 ±
0.374 (8)
8.06 ±
0.317 (12)
9.57 ±
0.186 (6)
7.57 ±
0.498 (7)

Control

Anoxia

Control

Anoxia

23.90 ±
0.779 (8)

21.68 ±
0.960 (5)

22.28 ±
0.879 (7)

22.45 ±
1.090 (7)

P14

Body weight (grams)

0.054 ±
0.0042 (7)

0.062 ±
0.0029 (6)

0.044 ±
0.0023 (12)

0.047 ±
0.0023 (8)

P4

0.084 ±
0.0034 (7)

0.103 ±
0.0024* (6)

0.083 ±
0.0025 (12)

0.083 ±
0.0046 (8)

P7

0.127 ±
0.0081 (8)

0.114 ±
0.0053 (5)

0.120 ±
0.0072 (7)

0.123 ±
0.0076 (7)

P14

Heart weight (grams)

0.0072 ±
0.0004 (7)

0.0065 ±
0.0003 (6)

0.0054 ±
0.0002 (12)

0.0055 ±
0.0002 (8)

P4

0.0066 ±
0.0002 (7)

0.0068 ±
0.0002* (6)

0.0061 ±
0.0002 (12)

0.0058 ±
0.0003 (8)

P7

0.0053 ±
0.0002 (8)

0.0053 ±
0.0001 (5)

0.0054 ±
0.0002 (7)

0.0055 ±
0.0002 (7)

P14

Heart to Body weight ratio

Table 3.1. Effect of newborn anoxia and PD156707 on body and heart weight of neonatal rats. Body
and isolated hearts were weighed from day 4, 7, and 14 neonatal rats that were treated with control or anoxia,
in the absence or presence of PD156707. Heart to body weight ratio values are also represented. Data are
means ± SEM. * P < 0.05, control -PD156707 vs. +PD156707. Number of animals is represented in
parentheses.!

Neonatal Anoxia Had No Effect on ET-Receptor Density
Hearts from postnatal day 4 rats that were treated with anoxia were collected and
protein isolated. There was no significant change in protein abundance of either ETAR or
ETBR, due to anoxia treatment (Figure 3.8).
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Figure 3.8. Effect of newborn anoxia on ETA- and ETB-receptor protein
abundance in the neonatal heart. Hearts were isolated from day 4 neonatal rats
treated with control or anoxia. Protein abundance of ETAR (A) and ETBR (B) was
determined by Western immunoblotting. Data are means ± SEM. n = 4-5!
72!

Prenatal Hypoxia Decreased Cardiomyocyte Proliferation in the Fetal
Heart
To investigate the comparative effect of prenatal hypoxia, pregnant rats were
treated with either normoxic control or 10.5% O2 from gestational day 15 to 21, and
hearts were isolated from postnatal day 4 and 7 neonatal rats. Similar to the findings in
newborn anoxia treatment, prenatal hypoxia resulted in a significant decrease in the
proliferation of cardiomyocytes at postnatal day 7 (Figure 3.9A), but had no significant
effects on percent binucleation (Figure 3.9B) or the heart to body weight ratio (Figure
3.9C).
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Figure 3.9. Effect of prenatal hypoxia on neonatal cardiomyocyte
proliferation, binucleation, and heart to body weight ratio. Cardiomyocytes
were isolated from day 4 and 7 neonatal rats that were treated with control or
maternal hypoxia. Cells were stained with α-actinin and Ki-67, and nuclei
stained with Hoechst. Panel A shows percent of Ki-67 expressing cells (n = 34). Panel B shows percent of binucleate cells (n = 4). Panel C shows the heart
to body weight ratio (n = 8-9). Data are means ± SEM. * P < 0.05, hypoxia vs.
control.!
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Discussion
In the present study, we provide evidence showing that in vivo newborn anoxia
leads to a decrease in the proliferation of cardiomyocytes in the developing heart.
Furthermore, our results suggest that anoxia treatment leads to a significant reduction in
number of cardiomyocytes per heart weight of the day 14 neonate, which is terminally
differentiated. The findings that anoxia increased ET-1 production in the heart and the
anoxia-induced changes in proliferation and cardiomyocyte number were reversed with
PD156707, suggest a mechanism mediated by the ETA-receptor. In addition, basal ET-1
was also found to play a role in cardiomyocyte proliferation, as well as the heart to body
weight ratio.
Cardiomyocytes undergo a terminal differentiation process that reaches
completion by the first two weeks of neonatal life in rats (Ahuja, Sdek, et al., 2007;
Clubb & Bishop, 1984). After this, cardiomyocytes in the heart have negligible
proliferative capacity and further growth is mainly via hypertrophy. Thus the number of
cardiomyocytes that will reside in the adult heart is determined during this early stage and
if altered may result in life-long consequences. Hypoxic stress during perinatal
development has been shown by previous studies to diminish the proliferation of
cardiomyocytes (Paradis et al., 2014; Tong et al., 2013; Tong et al., 2011). Furthermore,
fetal hearts exposed to hypoxia have fewer (Bae et al., 2003; Botting et al., 2014) and
larger cardiomyocytes (Bae et al., 2003), and adult male rats that were exposed to
hypoxia in utero were more susceptible to ischemic injury as seen by increased
myocardial infarction and reduced recovery (G. Li et al., 2003).
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Preterm birth is a complex clinical problem that is highly associated with episodes
of severe hypoxia and even anoxia, which can be so severe that the infant must be
mechanically ventilated (Bolivar et al., 1995). Preterm infants have an immature
respiratory system (Martin, Wang, Koroglu, Di Fiore, & Kc, 2011) that is unable to
provide adequate oxygen at times and thus ventilatory support is frequently needed.
However, several studies have shown that episodic airway obstruction and hypoxemia
commonly occur in these infants (Dimaguila, Di Fiore, Martin, & Miller, 1997;
Dransfield, Spitzer, & Fox, 1983). Given that the rodent heart is relatively immature at
birth, the present study with episodic anoxia treatments of newborn rats provides a
reasonable animal model to study the effects of anoxia/hypoxia on the heart development
in preterm infants. Anoxia itself has been shown to alter proliferation, and, in rat
fibroblasts, leads to arrest of the cell cycle at the G1 and S phase (Gardner, Li, Yang, &
Dang, 2003).
To confirm the extent of hypoxic exposure to the neonatal hearts used in our
study, the protein levels of hypoxia-inducible factor 1 alpha (HIF-1α) were evaluated.
The results show that HIF-1α!protein abundance is significantly increased in neonatal
hearts exposed to in vivo anoxia; furthermore increased levels of HIF-1α!in the heart have
also been observed in the prenatal hypoxia model (Bae et al., 2003). In agreement with
previous work, we showed that cardiomyocyte proliferation was decreased following in
vivo neonatal anoxia treatment at postnatal day 4 and 7. The cardiomyocytes take
approximately 24 hours for them to fully attach to the plate before the
immunocytochemical staining of Ki-67 can be performed. While the potential effect of
this attachment process on the rate of proliferation may not be excluded in the present
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study, the same procedure applied to all treatment groups. By postnatal day 14, there was
a trend for anoxia to decrease proliferation however this trend was not significant in our
data. The heart is thought to be fully mature and essentially an adult phenotype of
cardiomyocytes by day 14 in rats, therefore the rate of myocyte proliferation is normally
very low at this point and anoxia had no significant effect on lowering it further.
Similarly, our results from the prenatal hypoxia model showed a decrease in the
proliferation of neonatal cardiomyocytes at postnatal day 7. Interestingly, newborn
anoxia had no significant effect on the binucleation of cardiomyocytes. Previous work
has shown that maternal hypoxia leads to an increase in the amount of binucleate
cardiomyocytes in the fetal heart (Bae et al., 2003), thus indicating a development stagespecific effect.
Furthermore, we investigated two proteins that are closely involved in the
regulation of the cell cycle: cyclin D2 and p27. These proteins have previously been
studied and found to be differentially expressed in the hypoxia-treated fetal heart (Tong
et al., 2013). Cyclin D2 is associated with other cell cycle regulators that work to promote
cell cycle activity, while p27 is a cyclin-dependent kinase inhibitor and thus inhibits cell
cycle activity. Therefore the expression of these two proteins should be inversely related,
as our results indicate. Cyclin D2, a cell cycle promoter, is significantly decreased during
anoxia treatment, while the cell cycle inhibitor, p27, is upregulated under these
conditions. These results are consistent with our finding that anoxia treatment decreases
cardiomyocyte proliferation. In addition, we tested the role of ET-1 acting through its
ETAR on the expression of cyclin D2 and p27. In the presence of PD156707, an ETAR
antagonist, anoxia had no effect on cyclin D2 expression. However, p27 expression was
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significantly decreased in the presence of PD156707 compared to control conditions.
These findings suggest that ET-1 and the ETAR are key mediators in the anoxia-induced
effects on cyclin D2 and p27. Ultimately, these results may help to explain the overall
decrease in cardiomyocyte proliferation due to anoxia treatment.
Although a gradual decrease in proliferation in the critical window of the heart
development is a normal developmental process, hypoxia and anoxia appear to accelerate
this progression, particularly during the early development. The endpoint of
cardiomyocyte number is a metric to measure the consequence of altering the
proliferative capacity. Our results suggest that anoxia reduces cardiomyocyte endowment
at postnatal day 14, when the heart is presumed to be fully mature and cardiomyocytes
have terminally differentiated. Anoxia reduced proliferation at days 4 and 7, resulting in
fewer cardiomyocytes in the differentiated heart seen at day 14. Given that
cardiomyocytes are the functional contractile units of the heart, this decreased
cardiomyocyte endowment in the heart may have negative impact in cardiac function and
become more susceptible to injury later in life. While our results suggest a significant
reduction in cardiomyocyte endowment due to anoxia at the critical window of the heart
development, future studies using unbiased and random stereology will be needed to
provide conclusive evidence of this effect.
Previous studies from our laboratory and others have shown that hypoxia
regulates proliferation of cardiomyocytes and vascular muscle (Cooper & Beasley, 1999;
Paradis et al., 2014; Tong et al., 2013; F. X. Zhang et al., 2007). However the
downstream regulators of this response have yet to be identified. Our previous work in an
ex vivo model showed that primary fetal cardiomyocytes exhibited a similar decrease in
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proliferation when treated with endothelin-1 (ET-1) (Paradis et al., 2014). It is known that
ET-1 expression is induced under hypoxic conditions via a HIF-binding site on its
promoter (Hashiguchi et al., 1991; Hu et al., 1998; Minchenko & Caro, 2000; Ostlund et
al., 2000; Yamada et al., 2001; Yamashita et al., 2001), specifically in cardiomyocytes
(Kakinuma et al., 2001). ET-1 itself has also been shown to regulate proliferation, having
a mitogenic effect on vascular smooth muscle (Agapitov & Haynes, 2002; Goldie, 1999;
Komuro et al., 1988). Moreover our results showed an increase in prepro-ET-1 mRNA in
the P4 neonatal heart when exposed to anoxia. Previous work has also shown an increase
in prepro-ET-1 mRNA in the fetal heart exposed to maternal hypoxia (Paradis et al.,
2014). These studies taken together implicate a role for ET-1 in mediating the hypoxiaand anoxia-induced decrease in cardiomyocyte proliferation.
A selective ET-receptor antagonist was used to study the role of both basal and
anoxia-induced ET-1 in the present study. ET-1 can activate two receptor subtypes: the
ETA- and ETB-receptor. Activation of the ETA-receptor leads to vasoconstriction and is
primarily found in vascular muscle (Hosoda et al., 1991). In contrast, the ETB-receptor
can provide a vasodilation effect as well as vasoconstriction depending on the receptor
location, in endothelial cells (Sakurai et al., 1990) or vascular muscle (Arai et al., 1990;
Kawanabe & Nauli, 2011; Sakurai et al., 1990; Yanagisawa, 1994), respectively. The
ETB-receptor also plays a role in the clearance of endothelin from tissues (Wilkes et al.,
1993). In cardiomyocytes, the ETA-receptor is the predominant subtype (Kohan et al.,
2011), and has been implicated in regulating proliferation (Agapitov & Haynes, 2002;
Goldie, 1999; Komuro et al., 1988). Therefore, our study evaluated the effects of
PD156707, a selective antagonist for the ETA-receptor (Reynolds et al., 1995), on
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cardiomyocyte proliferation. Due to the short half-life of PD156707 of about one hour
(Coe, Haleen, Welch, Liu, & Coceani, 2002), it was given twice a day just prior to anoxia
exposure in the present study. We also evaluated the protein expression of the ETreceptors, both ETAR and ETBR. Interestingly, the results showed no change in the
expression of either receptors due to anoxia treatment, suggesting that a change in
receptor density is not contributing to the effects of anoxia or ET-1. The finding that
PD156707 ameliorated the anoxia-induced decrease in proliferation of cardiomyocytes at
day 4 and 7 implicates the ETA-receptor as a key mediator. Furthermore, the addition of
PD156707 alone elicited an increase in proliferation at day 4 beyond that of the control.
This observation was not seen at day 7 or day 14, suggesting that the regulation of basal
ET-1 function in the heart is dependent on the stage of development. At an earlier stage,
basal ET-1 levels play a key role in regulating cardiomyocyte proliferation. The effect of
basal ET-1 in regulating cardiomyocyte endowment in the developing heart is intriguing.
The treatment of newborn rats with ETA-receptor antagonist led to an increase in
cardiomyocyte number per heart weight at day 7, suggesting that an appropriate level of
basal ET-1 is necessary to optimize cardiomyocyte endowment in the heart.
Anoxia treatment had no significant effect on mononucleate and binucleate cell
size, however inhibition of ETAR by PD156707 caused an increase in cell size at day 7.
This may suggest that basal ET-1 plays a role in maintaining cell size and, and if
activation of the ETA-receptor is blocked, the cell undergoes hypertrophy. The change in
binucleate cell size is likely more relevant because the mononucleate cells still have the
capacity to divide and are not yet terminally differentiated.
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The heart to body weight ratio was unchanged with anoxia treatment for all age
groups. However by blocking basal ET-1 with PD156707, the heart to body weight ratio
was increased at postnatal day 7. These results suggest that the heart is increasing in size,
which agrees with the results of increased cell size, proliferation, and cardiomyocyte
number in the presence of PD156707. In the present study, the cardiomyocyte number
were counted in freshly isolated myocytes, and the in vivo PD156707 treatment increased
the cardiomyocyte number by about 65% in day 7 hearts. It has been previously
demonstrated in neonatal rats that the heart contains approximately 25% cardiomyocytes
(Banerjee, Fuseler, Price, Borg, & Baudino, 2007; Walsh, Ponten, Fleischmann, &
Jovinge, 2010). If the PD156707 treatment induced proportional changes in the nonmyocyte composition of the heart, it might increase the cardiomyocyte composition in the
heart to around 42%, albeit the proliferation of non-myocyte cells in the heart could be
differentially regulated. It is important to note that although changes in cardiomyocyte
size measured in cells that were attached to plates suggest a physiological difference due
to the PD156707 treatment, they are not necessarily representative of what's happening in
vivo. It is likely that the increases of both cardiomyocyte number and cell size contribute
to the increased heart weight observed at day 7 neonatal rats. The finding that the heart to
body weight ratio is unchanged at day 14 even though anoxia treatment decreases
cardiomyocyte endowment implies that the cardiomyocytes may increase their size to
compensate for the loss of cells and maintain the size of the heart. However, we were
unable to measure cardiomyocyte size from the day 14 hearts due to technical limitations
and their poor attachment to the culture plate at this stage. Another possibility includes an
increase in non-cardiomyocyte cell number and size in the heart after anoxia treatment.
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The present study evaluated not only the effects of newborn anoxia treatment on
the terminal differentiation of neonatal cardiomyocytes but also the role of basal ET-1 on
this process. We identified a mechanism through which neonatal anoxia exposure induces
an accelerated loss of cardiomyocyte proliferation via the ETA-receptor, which
subsequently results in reduced cardiomyocyte endowment in the fully differentiated
heart. Our study also demonstrated the role that basal ET-1 plays in regulating
cardiomyocyte size, proliferation, and number in the developing heart. Given the clinical
implications of these findings in understanding the effects of hypoxia on the heart
development in preterm infants, further investigation into the mechanisms involved is
needed.
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CHAPTER FOUR
ENDOTHELIN-1-INDUCED CHANGES IN THE FETAL CARDIOMYOCYTE
PROTEOME

By
Alexandra Paradis, Chiranjib Dasgupta, and Lubo Zhang
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Abstract
Hypoxia is a fetal stressor that is known to lead to the production of endothelin-1
(ET-1). Previous work has shown that ET-1 treatment leads to the premature terminal
differentiation of fetal cardiomyocytes, however the mechanism is, as of yet, unknown.
We tested the hypothesis that the fetal cardiomyocyte proteome will be greatly altered
due to ET-1-treatment, revealing a potential molecular mechanism of ET-1-induced
terminal differentiation. Over a thousand proteins were detected in the fetal
cardiomyocytes and of that 75 proteins were significantly altered due to ET-1 treatment.
Following pathway analysis, the merged network depicted several key proteins that
appear to be involved in regulating proliferation, including: EED, UBC, ERK1/2, MAPK,
Akt, and EGFR. Of particular interest is the EED protein, which is associated with
regulating proliferation via epigenetic mechanisms. Herein we propose a model of the
molecular mechanism by which ET-1 induced cardiomyocyte terminal differentiation
occurs.

Introduction
There is compelling evidence indicating that an adverse intrauterine environment
can result in an increased vulnerability to cardiovascular disease later in adult life
(Barker, 1995; Barker & Osmond, 1986). Environmental stress factors during fetal
development can impact the growth and maturation of critical organs in the developing
fetus, such as the heart. Hypoxia is one major stress factor to the developing fetus.
Previous studies have shown that a hypoxic environment results in the premature terminal
differentiation of fetal cardiomyocytes (Bae et al., 2003; Paradis et al., 2014; Tong et al.,
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2013; Tong et al., 2011), characterized by decreased proliferative capacity. Terminal
differentiation is the final step in the maturation of cardiomyocytes and it occurs in a
timeframe surrounding birth. Cardiomyocytes undergo cell-cycle withdrawal soon after
birth, and the majority of postnatal cardiac growth is due to cardiomyocytes growing in
size with very little proliferation (Bergmann et al., 2009). Studies have shown that
hypoxia accelerates this maturation process and can ultimately lead to fewer
cardiomyocytes endowed within the heart (Bae et al., 2003). The heart is fully mature
shortly after birth and thus the timing of this transition is crucial in determining the
number of cardiomyocytes that will reside in the heart for a lifetime. If this timeline is
perturbed, it may lead to long-term detrimental consequences on heart development and
function throughout life.
Several in vivo and in vitro fetal studies have shown the effect of hypoxia on fetal
heart development, however the mechanisms remain largely unknown. Our recent studies
have suggested a role for endothelin-1 (ET-1) in hypoxia-induced terminal differentiation
of cardiomyocytes (Paradis et al., 2014). Hypoxia is known to induce ET-1 expression
(Hashiguchi et al., 1991; Ostlund et al., 2000; Yamada et al., 2001; Yamashita et al.,
2001), and the cardiomyocyte is both a site of synthesis and action of ET-1 (Kedzierski &
Yanagisawa, 2001; Kohan et al., 2011). Although ET-1 has been implicated in the
accelerated terminal differentiation process, the protein regulators downstream to ET-1
are unknown.
Therefore, in the present study we tested the hypothesis that ET-1 alters the
expression of key regulatory proteins involved in cardiomyocyte terminal differentiation.
Herein, we provide evidence that ET-1 treatment differentially regulates expression of
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key proteins involved in the maturation and proliferation of fetal cardiomyocytes. Our
proteomics experiment identified seventy-five (75) proteins that were previously
unknown to be differentially modulated by ET-1 treatment in fetal cardiomyocytes.
Collectively, the effect of these proteins may describe the molecular mechanism(s) that
dictate(s) accelerated terminal differentiation of cardiomyocytes.

Materials and Methods
Experimental Animals
Time-dated pregnant Sprague-Dawley rats were purchased from Charles River
Laboratories (Portage, MI). Hearts were isolated from day 21 fetuses, as previously
described (Paradis et al., 2014). To isolate hearts, pregnant rats were anesthetized with
isoflurane, and adequate anesthesia was determined by loss of pedal withdrawal reflex.
Fetuses were removed and pregnant rats killed by removing the hearts. Fetal hearts were
isolated for the studies. All procedures and protocols were approved by the Institutional
Animal Care and Use Committee and followed the guidelines by US National Institutes
of Health Guide for the Care and Use of Laboratory Animals.

Primary Cardiomyocyte Culture and Treatment
Cardiomyocytes were isolated from day 21 fetal rats as previously described
(Paradis et al., 2014; Y. Xiao et al., 2000). Briefly, hearts were enzymatically digested
then preplated to further enrich in cardiomyocytes. Cells were cultured in Hyclone
Medium 199 (Thermo Scientific) supplemented with 10% fetal bovine serum (Gemini
Bio-Products) and 1% antibiotics (10,000 I.U./mL penicillin, 10,000 µg/mL
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streptomycin) at 37°C in 95% air/5% CO2. BrdU (0.1mM) was added to the medium to
prevent fibroblast proliferation. Within three days of culture, the cells formed a
monolayer with synchronized beating, characteristic of viable cardiomyocytes. Cells
were treated in the absence or presence of ET-1 (Sigma; 10 nM) in the growth media at
70-80% confluency for 24 hours.

Proteomic Analysis
Analysis of the isolated primary cardiomyocytes proteome was done before and
after ET-1 treatment by Tandem Mass Tag (TMT) labeling of the peptides followed by
tandem mass tags (TMTs)-LC-MS/MS analysis with an LTQ-Orbitrap-Pro instrument as
previously described (D. Xiao et al., 2014; L. Xiong et al., 2011; K. Zhang et al., 2012).
TMT reagents belong to a family of reagents known as isobaric mass tags, which provide
a high throughput alternative to immunoblot based quantitation.
Primary fetal cardiomyocytes were homogenized in RIPA lysis buffer (Santa Cruz
Biotechnology) containing protease inhibitors and protein concentrations were
determined using the BCA assay (ThermoScientific). Proteins were reduced by 50 mM
DTT in triethyl ammonium bicarbonate buffer (TEAB) at 55°C for 30 minutes and then
alkylated with 50 mM 2-iodoacetamide (IAA) for 45 minutes at room temperature in
dark. Next, proteins were precipitated with acetone (80% v/v of acetone) and
reconstituted in 90 µl TEAB. An aliquot of 100 µg proteins was digested with 4 µg of
freshly prepared trypsin (Sigma) at 37°C for at least 10 hours. Resulting peptides were
TMT labeled at their N-term end by TMT duplex kit (Thermoscientific) according to the
manufacture’s instructions. Samples!from!each!treatment!group!were!TMTBlabeled!
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with!one!of!the!respective!reporters!at!m/z=!126.1!(control)!and!127.1!(ETB1,!
10nM). Each TMT-labeled protein pool was acidified with 0.1% formic acid (FA) and
fractionated with strong cation-exchange (SCX) chromatography on a Toptip column
(Poly LC, MD). For fractionation, the matrix was equilibrated with 0.1% FA in 20%
acetonitrile (ACN) to facilitate peptide binding. After collection of the flow-through
(FT), 1 mL of each subfraction was sequentially eluted with solvents, 50 mM KCl, 200
mM KCl, and 5% ammonium hydroxide in 20% ACN. Next, the fractions were dried
under vacuum to remove ACN, reconstituted in 1% FA, and then desalted using a Toptip
column with C18/hypercarb mixed materials (Poly LC, MD). The eluted peptides were
once again vacuum-dried, reconstituted in 30 µl of 0.1% FA, and then subjected to LCMS/MS analysis. The LC-MS/MS analysis was performed as described previously (K.
Zhang et al., 2012). Quantitation of SCX fractionated TMT-labeled peptides was carried
out on the Thermo LTQ-Orbitrap Pro mass spectrometer. Peptides were separated by
online reversed phase liquid chromatography (RPLC) using an Easy-nLC that is equipped
with an autosampler (Thermo Scientific). A 10 cm, 75 µm id, 3 µm particle size, C18-A2
analytical column (Thermo) was used for the RPLC separations. Approximately 3.2 µg of
peptide sample was injected. A pre-column (Thermo, 0.1 x 2 cm, 5 µm C18-A1)
connected in line preceding the analytical column and a 200-min gradient (solvent A,
0.1% FA in water; solvent B, 0.1% FA in ACN) from 5-30% solvent B was used for
separating the peptides. The Orbitrap mass analyzer was set to acquire data at 60,000
resolution for the parent full-scan mass spectrum followed by data-dependent high
collision-energy dissociation (HCD) MS/MS spectra for the top 10 most abundant ions
acquired at 7500 resolution. Mass Spectrometry data were processed and searched against
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rat protein database through the Thermo Scientific Proteome Discoverer 1.3 platform
using SEQUEST search engine with parameters as previously described (L. Xiong et al.,
2011). Protein expression levels (i.e., fold change values of protein expression in ET-1
treated group relative to control) were expressed as the ratios of the intensities of reporter
ions (127/126). We applied the following criteria for data analysis. For a protein
expression fold change to be considered significant, a fold change cut-off value of 1.146
(more than 14.6% up-or down-regulation) was used. Though our previous work (D. Xiao
et al., 2014) along with others (L. Xiong et al., 2011; K. Zhang et al., 2012) used a cut-off
value of 1.2 for similar isobaric TMT labeling experiments, in this study we used a
slightly relaxed cut-off value to include changes in expression those proteins that would
otherwise fall just short of being significant and that these proteins may also be of
physiological significance. For a protein to be considered correctly detected with unique
peptides, respective MS/MS spectrum was checked on Proteome Discoverer (version 1.3)
and only accepted if the major product ions matched the theoretically predicted product
ions from the database. Subsequently, Ingenuity Pathway Analysis (IPA) tool (Qiagen)
was used to decipher molecular pathway relationships between significantly modulated
proteins in the form of network maps.

Results
Endothelin-1 Alters the Fetal Cardiomyocyte Proteome
A total of more than a thousand proteins were identified in the fetal
cardiomyocytes by one-dimensional LC-MS/MS approach. Of these proteins, the
expression of 75 proteins was differentially modulated due to endothelin-1 treatment
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compared to untreated control groups (Table 4.1). IPA pathway analysis was performed
using stringent filter (rodent) to decipher relationships amongst the modulated proteins.
This analysis revealed that the modulated proteins were distributed into five discrete
networks 1 thru 5 corresponding to Figures 2 thru 6, which are presented here with their
sub-cellular distribution. Figure 4.1A depicts the merged network map, whose keys are
presented in Figure 4.1B. The proteins associated with each network as well as their
known functions are depicted in Table 4.2. Figures 4.7, 4.8, 4.9, and 4.10 are network
maps of those proteins that are interacting with the four major convergence points
(proteins): 1) EED, 2) UBC, 3) ERK/p38 MAPK/Akt/RhoA, and 4) EGFR respectively.
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Figure 4.1. Merged network map showing endothelin-1-induced changes in
the fetal cardiomyocyte proteome. Primary fetal cardiomyocytes were treated
with control or endothelin-1 (10 nM) for 24 hours. Protein expression analysis
was performed in fetal cardiomyocytes by TMT-LC-MS/MS analysis with a
LTQ-Orbitrap-Velos instrument. IPA pathway analysis using the stringent filter
(rodent) revealed five separate sub-networks for endothelin-1-modulated
proteins. Panel A depicts a merged network of all the proteins detected. Panel
B is the key. The network is represented based on sub-cellular distribution.!

91!

Shape
Cytokine
Enzyme
G-protein Coupled Receptor

Relationship

Color key

B
A
Abinding B

Red:
up-regulation
Green: down-regulation
Purple: new relationship due to
merging of endothelin-1
induced sub-networks
or protein super family

A
B
A acts on
B

Kinase
Peptidase

!

Ligand-dependent Nuclear Receptor

self regulation

92

Phosphatase
Transcription Regulator

direct interaction

Transmembrane Receptor

indirect interaction

Transporter
Complex/Group
Mature microRNA
Other
Translation regulator

Figure 4.1B. IPA network keys!

!

Figure 4.2. Network 1. ET-1 induced proteins, which are known to be involved in
organ morphology, skeletal and muscular system development and function, and
embryonic development. The network is represented based on sub-cellular
distribution.
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Figure 4.3. Network 2. ET-1 induced proteins, which are known to be involved in
cancer and infectious diseases. The network is represented based on sub-cellular
distribution.
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Figure 4.4. Network 3. ET-1 induced proteins, which are known to be involved in
gene expression and organismal injury and abnormalities. The network is
represented based on sub-cellular distribution.

95#

Figure 4.5. Network 4. ET-1 induced proteins, which are known to be involved in
cellular assembly and organization, tissue development, and molecular transport.
The network is represented based on sub-cellular distribution.
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Figure 4.6. Network 5. ET-1 induced proteins, which are known to be involved in
RNA post-transcriptional modification, post-translational modification, and
connective tissue disorders. The network is represented based on sub-cellular
distribution.
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Figure 4.7. EED interacting proteins. The ET-1 induced cardiomyocyte
proteome reveals a large number of proteins that are interacting with EED
(embryonic ectoderm development), a potential key player in the ET-1 induced
effects on the cardiomyocyte.
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Figure 4.8. UBC interacting proteins. The ET-1 induced cardiomyocyte
proteome reveals a large number of proteins that are interacting with UBC
(ubiquitin protein C), one of the major convergence points in the merged
network map.
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Figure 4.9. ERK1/2 interacting proteins. The ET-1 induced
cardiomyocyte proteome reveals a large number of proteins that are
interacting with ERK1/2, a key protein involved in cell survival and
proliferation.
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Figure 4.10. EGFR interacting proteins. The ET-1 induced
cardiomyocyte proteome reveals a large number of proteins that are
interacting with EGFR (epidermal growth factor receptor), another
major convergence points in the merged network map.
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Figure 4.11. Proposed mode of action of ET-1. Endothelin-1 stimulates
cardiomyocyte terminal differentiation and decreases proliferation, whereas the
EED protein is known to do the opposite. The proposed model illustrates a
mechanism by which ET-1 induces UBC, which may lead to a downregulation of
EED and thus inhibit its effect on proliferation and differentiation.
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Table 4.1. Endothelin-1-mediated changes in the fetal cardiomyocyte proteome. Represented
is a list of 75 proteins whose expression was altered by ET-1 treatment of the fetal
cardiomyocyte. The fold change (126/127) refers to the change in protein expression in
cardiomyocytes treated with 10nM ET-1 compared to control.
127/126 ±! Fold
SEM#
Change#

Accession ##

Entrez Gene Name#

Location#

IPI00777957.2#

acid phosphatase 2, lysosomal#

Cytoplasm#

0.859 ±#
0.014#

-1.164#

IPI00189813.1#

actin, alpha 1, skeletal muscle#

Cytoplasm#

0.736 ±#
0.039#

-1.358#

IPI00189819.1#

actin, beta#

Cytoplasm#

0.759 ±#
0.022#

-1.317#

IPI00200455.1#

actin, gamma 2, smooth muscle, enteric#

Cytoplasm#

0.746 ±#
0.016#

-1.340#

IPI00363022.4#

actinin, alpha 2#

Nucleus#

0.795±#
0.050#

-1.258#

IPI00213463.2#

actinin, alpha 4#

Cytoplasm & Nucleus#

0.846 ±#
0.048#

-1.182#

IPI00763263.2#

Aly/REF export factor#

Nucleus#

0.863 ±#
0.029#

-1.158#

IPI00199911.2#

ADP-ribosylation factor interacting protein 1#

Cytoplasm#

2.465 ±#
0.058#

2.465#

Plasma Membrane#

0.843 ±#
0.021#

-1.186#

IPI00365705.6# ATPase, H+/K+ exchanging, alpha polypeptide#
IPI00952436.1#

ATPase, H+ transporting, lysosomal 50/57kDa,
V1 subunit H#

Cytoplasm#

1.148 ±#
0.056#

1.148#

IPI00480620.1#

3-hydroxybutyrate dehydrogenase, type 1#

Cytoplasm#

0.866 ±#
0.106#

-1.155#

IPI00372004.3#

basic transcription factor 3#

Nucleus#

0.781 ±#
0.017#

-1.282#

IPI00565758.1#

CDV3 homolog (mouse)#

Cytoplasm#

1.157 ±#
0.010#

1.157#

IPI00364337.3#

charged multivesicular body protein 6#

Cytoplasm#

1.224 ±#
0.044#

1.224#

IPI00201505.3#

CCHC-type zinc finger, nucleic acid binding
protein#

Nucleus#

0.846 ±#
0.104#

-1.182#

IPI00780087.2#

collagen, type IV, alpha 1#

Extracellular Space#

0.771 ±#
0.086#

-1.305#

IPI00230832.7#

cytochrome c oxidase subunit VIc#

Cytoplasm#

0.847 ±#
0.045#

-1.181#

IPI00370154.3#

cleavage and polyadenylation specific factor 1,
160kDa#

Nucleus#

0.804 ±#
0.013#

-1.243#
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IPI00562653.2#

cathepsin B#

Cytoplasm#

0.839 ±#
0.016#

-1.192#

IPI00370330.4#

cut-like homeobox 1#

Nucleus#

0.806 ±#
0.030#

-1.241#

IPI00373131.3#

DDRGK domain containing 1#

Extracellular Space#

1.167 ±#
0.009#

1.167#

IPI00421517.7#

desmin#

Cytoplasm#

1.296 ±#
0.030#

-1.296#

IPI00230946.4#

dipeptidyl-peptidase 7#

Cytoplasm#

0.861 ±#
0.083#

-1.162#

IPI00372810.5#

eukaryotic translation initiation factor 3, subunit
A#

Cytoplasm#

0.866 ±#
0.029#

-1.155#

IPI00947800.1#

echinoderm microtubule associated protein like
2#

Cytoplasm#

0.867 ±#
0.005#

-1.153#

IPI00365904.4#

glutaredoxin 5#

Cytoplasm#

0.765 ±#
0.045#

-1.306#

IPI00471669.1#

glypican 4#

Plasma Membrane#

0.868 ±#
0.060#

-1.151#

IPI00231976.7#

histone cluster 1, H2ba#

Nucleus#

0.801 ±#
0.036#

-1.248#

IPI00393508.3#

histone cluster 1, H2bb#

Nucleus#

0.486 ±#
0.054#

-2.058#

IPI00767428.2#

histone cluster 1, H3i#

Nucleus#

0.57 ±#
0.033#

-1.754#

IPI00476722.4#

histone cluster 2, H3a#

Nucleus#

0.518 ±#
0.058#

-1.931#

IPI00960040.1#

histone cluster 4, H4#

Nucleus#

0.646 ±#
0.047#

-1.549#

IPI00199887.1#

junctophilin 2#

Cytoplasm#

0.85 ±#
0.028#

-1.177#

IPI00382153.4#

keratin 5#

Cytoplasm#

1.233 ±#
0.072#

1.233#

IPI00421781.1#

keratin 72#

Other#

1.328 ±#
0.052#

1.328#

IPI00421812.1#

keratin 76#

Cytoplasm#

1.178 ±#
0.066#

1.178#

IPI00231014.1#

LIM domain kinase 2#

Cytoplasm#

0.87 ±#
0.015#

-1.149#

IPI00201060.4#

lamin A/C#

Nucleus#

0.81 ±#
0.059#

-1.235#
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IPI00958096.1#

GF20391-like#

Other#

0.734 ±#
0.065#

-1.362#

IPI00959660.1#

RAB1B, member RAS oncogene family-like#

Other#

0.829 ±#
0.076#

-1.207#

IPI00957208.1#

keratin 6A-like#

Other#

1.179 ±#
0.086#

1.179#

Other#

1.195 ±#
0.030#

1.195#

IPI00203211.4# leucine rich repeat (in FLII) interacting protein 1#
IPI00211813.2#

myosin, heavy chain 10, non-muscle#

Cytoplasm#

0.872 ±#
0.035#

-1.146#

IPI00230979.1#

nicotinamide phosphoribosyltransferase#

Extracellular Space#

0.863 ±#
0.101#

-1.158#

IPI00201261.2#

nestin#

Cytoplasm#

0.806 ±#
0.033#

-1.240#

IPI00365822.3#

ninein (GSK3B interacting protein)#

Cytoplasm#

0.822 ±#
0.072#

-1.216#

IPI00831725.1#

nitrilase 1#

Cytoplasm#

0.834 ±#
0.053#

-1.200#

IPI00364693.3#

NOP2/Sun RNA methyltransferase family,
member 2#

Nucleus#

0.85 ±#
0.060#

-1.176#

IPI00366831.3#

OTU domain containing 6B#

Other#

1.163 ±#
0.078#

1.163#

IPI00949808.1#

PDZ and LIM domain 5#

Cytoplasm#

1.164 ±#
0.055#

1.164#

IPI00370658.1#

pinin, desmosome associated protein#

Plasma Membrane#

1.178 ±#
0.092#

1.178#

IPI00365600.3#

protein kinase, cAMP-dependent, regulatory,
type II, beta#

Cytoplasm#

0.846 ±#
0.028#

-1.181#

IPI00194524.1#

phosphoribosyl pyrophosphate synthetaseassociated protein 2#

Other#

1.59 ±#
0.170#

1.590#

IPI00367437.5#

RNA binding motif (RNP1, RRM) protein 3#

Cytoplasm#

0.869 ±#
0.016#

-1.151#

IPI00565999.1#

similar to H3 histone, family 3B#

Other#

0.752 ±#
0.090#

-1.329#

IPI00567981.3#

similar to Histone H3.3#

Other#

0.805 ±#
0.017#

-1.243#

IPI00777683.2#

similar to pyridoxal (pyridoxine, vitamin B6)
kinase#

Other#

0.83 ±#
0.037#

-1.204#

IPI00196562.3#

RIC8 guanine nucleotide exchange factor A#

Cytoplasm#

0.85 ±#
0.005#

-1.176#
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IPI00764478.2#

small ArfGAP 1#

Cytoplasm#

0.865 ±#
0.035#

-1.156#

IPI00949260.1#

sorting nexin 18#

Cytoplasm#

0.867 ±#
0.021#

-1.153#

IPI00365613.2#

sorting nexin 6#

Cytoplasm#

1.186 ±#
0.157#

1.186#

IPI00231263.3#

structure specific recognition protein 1#

Nucleus#

0.857 ±#
0.114#

-1.166#

IPI00364043.4#

symplekin#

Cytoplasm#

0.87 ±#
0.059#

-1.149#

IPI00205262.5#

synaptopodin 2#

Cytoplasm#

0.87 ±#
0.053#

-1.149#

IPI00362425.1#

troponin C type 1 (slow)#

Cytoplasm#

0.861 ±#
0.005#

-1.162#

IPI00231699.5#

troponin I type 1 (skeletal, slow)#

Cytoplasm#

0.869 ±#
0.053#

-1.151#

IPI00197888.2#

tropomyosin 1, alpha#

Plasma Membrane#

0.813 ±#
0.039#

-1.230#

IPI00187731.4#

tropomyosin 2, beta#

Cytoplasm#

0.86 ±#
0.059#

-1.163#

IPI00196557.4# translin-associated factor X interacting protein 1#

Cytoplasm#

0.853 ±#
0.096#

-1.172#

IPI00554003.3#

titin#

Cytoplasm#

0.73 ±#
0.047#

-1.370#

IPI00361693.1#

twinfilin actin-binding protein 1#

Cytoplasm#

0.847 ±#
0.063#

-1.180#

IPI00957757.1#

unc-80 homolog (C. elegans)#

Cytoplasm#

0.839 ±#
0.019#

-1.192#

IPI00230941.5#

vimentin#

Cytoplasm#

0.78 ±#
0.039#

-1.282#

IPI00400610.4#

vacuolar protein sorting 13 homolog B (yeast)#

Nucleus#

1.196 ±#
0.011#

1.196#

IPI00564521.2#

widely interspaced zinc finger motifs#

Nucleus#

0.86 ±#
0.021#

-1.162#

Data are mean ± SEM.
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Table 4.2. Top diseases and functions associated with each network. The proteins are
categorized into 5 networks and pathway analysis reveals the major functions and diseases
that these groups of proteins are known to be associated with.
Network#

Top Diseases and
Functions#

1#

Organ Morphology,
Skeletal and Muscular
System Development
and Function,
Embryonic
Development#

2#

Cancer,
Gastrointestinal
Disease, Infectious
Disease#

3#

Gene Expression,
Cancer, Organismal
Injury and
Abnormalities#

4#

Cellular Assembly and
Organization, Tissue
Development,
Molecular Transport#

5#

RNA PostTranscriptional
Modification, PostTranslational
Modification,
Connective Tissue
Disorders#

Focus
Molecules#

Molecules in Each Network#

22#

ACTA1, ACTB, ACTG2, Actin, ACTN2, ACTN4,
Alpha Actinin, CD3, Cofilin, COL4A1, CTSB,
Cytokeratin, DES, ERK1/2, F Actin, G-Actin, Histone
h3, LIMK2, Mek, MYH10, Myosin, NAMPT, Nes,
NIT1, PDLIM5, RBM3, Rock, Tni, TNNC1, TNNI1,
Tpm1, Tpm2, TTN, TWF1, VIM#

15#

ARF3, ARF5, ARFIP1, ASCC3, CDC42BPA, CDV3,
CHMP6, CHMP4A, CHMP4B, DDRGK1, DDX3Y,
DPP7, EML2, HIST1H3I, IPO13, JPH2, KRT76,
LARP4B, METTL9, NIN, NXN, OTUD6B, PKD1,
PRKD2, RPF2, SMAP1, SNF8, SNX8, SNX18,
SYNPO2, UBC, USP54,V PS25, VPS36, VPS13B#

14#

ACP2, Akt, ALYREF, BTF3, CDH15, Ck2, CNBP,
CUX1, Cyclin A, DNTTIP2, EIF5, EIF3A, estrogen
receptor, FSH, HIST1H2BA, HIST2H3A, HIST4H4,
Histone h4, IL1, Insulin, KDM5A, KRT72, Lh,
LMNA, Nes, NFkB (complex), P38 MAPK, PDAP1,
PDLIM3, PRDM2, PRKAR2B, Rnr, SSRP1, Vegf,
ZNF519#

11#

AOC3, APP, ARL6IP5, ATP4A, ATP6V1A,
ATP6V1G1, ATP6V1H, BDH1, Cox6c, cyclic AMP,
EGFR, EIF2B2, ETHE1, FAM3B, FGF2, ganglioside
GM2, GLRX5, GPC4, peptidase, PNN, PRPSAP2,
RHOA, RIC8A, RUSC1, SCAMP3, SNX1, SNX4,
SNX6, SOX9, TBRG4, TCIRG1, TPRA1, TSNAXIP1,
USP6NL, ZCCHC17#

7#

CEP290, CLK2, Cpsf, CPSF1,C PSF2, CPSF3,
CPSF4, CPSF6, CSTF2, CSTF-CPSF-SYMPK,
DDX42, EED, EHMT1, EIF3D, GPI, HIST4H4,
HNRNPL, Ighg2a, KRT5, LOC100360950, NSUN2,
NUP188, PABPN1, PAPOLA, PCBP2, PKP2, POGZ,
RAB5C, SENP2, SMARCAD1, SUMO3, SYMPK,
TSEN15, VPRBP, WIZ#
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Discussion
This present study identified proteins that were modulated due to ET-1 treatment
of the fetal cardiomyocyte. Most of these proteins were found to be significantly
downregulated (green color) with some that were significantly upregulated (red color).
The proteins involved in each of the 5 networks are depicted in Table 4.2. When multiple
pathways are merged, several convergence points (proteins) were identified. These
proteins may indicate key regulators of the fetal cardiomyocyte proteome due to ET-1
treatment (Figure 4.1A).
Of particular interest is the convergence of numerous interacting proteins (Figure
4.7) with EED (embryonic ectoderm development), which is located at the bottom left of
the merged network map (Figure 4.1). EED is a member of the Polycomb group (PcG)
proteins, which are important transcriptional repressors (Boyer et al., 2006). These
proteins repress transcription of several key developmental regulators that would
otherwise promote cell differentiation. It is a key component of the PRC2 complex, along
with EZH2 and SUZ12, which is involved in histone modification and subsequent gene
silencing (T. I. Lee et al., 2006). Though EED per se, did not show any significant
changes in our study, several interacting protein partners of EED, e.g., LMNA, VIM,
TTN, PNN, ACTB, ACTN 4, COL4A1, Histone cluster 2 were down-regulated (Figure
4.7). Consequently and cumulatively this situation may compromise the function of EED
as well as of PRC2 complex. Our IPA analyses mapped all modulated proteins that
interact with EED (Figure 4.7). These findings are in agreement with Biogrid database
(http://thebiogrid.org).
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Several studies have demonstrated the important role of the PRC2 complex in
development. For example, the deletion of EED results in perinatal lethal heart defects
and thinned myocardium (He et al., 2012). Inactivation of EED in fetal cardiomyocytes
led to an upregulation in developmental and cell cycle regulators (He et al., 2012).
Additionally, it was shown that Ezh2 promotes cardiomyocyte proliferation by
suppressing the cell cycle inhibitors, Ink4a and Ink4b (He et al., 2012).
The results of this present study implicate EED as a potential key regulator of
endothelin-1-induced effects. Figure 4.7 illustrates a large number of interactions that
EED has with various identified proteins following ET-1 treatment. Considering the role
EED plays within the PRC2 complex to suppress gene transcription, it is possible that
this protein is regulating the expression of several of the other proteins identified in this
study. Most of the proteins revealed in this study were downregulated due to ET-1
treatment, several of which are involved in organ morphology and development. Our
previous work (Paradis et al., 2014) demonstrated that ET-1 treatment of fetal
cardiomyocytes resulted in increased terminal differentiation, characterized by increased
binucleation and decreased proliferation. These morphological changes are crucial to the
overall development of the heart and its function throughout a life. This present study
reveals that the protein EED may be a key regulator of the morphological and functional
changes previously observed by ET-1 treatment.
The second convergence point is found in the center of the merged network map
(Figure 4.1), surrounding UBC (ubiquitin C). This protein is depicted as interacting with
numerous other proteins that were identified via the pathway analysis (Figure 4.8). UBC
is an ubiquitin precursor and a source of ubiquitin proteins. Ubiquitin can be conjugated
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to other various proteins and in turn targets them for proteasomal degradation. Based on
the network map, it appears that UBC is interacting with the majority of proteins
identified in this study. That being said, it may be possible that UBC is involved in the
downregulation of many of the mapped proteins, including EED. A study has shown that
the level of PRC2 can be regulated by ubiquitination (Zoabi, Sadeh, de Bie, Marquez, &
Ciechanover, 2011). This complex is actually dissociated into the individual units (EED,
Ezh2, and SUZ12), which are then ubiquitinated and degraded (Zoabi et al., 2011).
Therefore this study provides evidence that ubiquitin can be conjugated to EED, leading
to its degradation. The pathway analysis suggests UBC is a key regulator of the protein
changes observed following ET-1 treatment. Of particular interest is the likelihood that
UBC is regulating another key player, EED, involved in the ET-1-induced fetal
cardiomyocyte proteome (Figure 4.11).
The two proteins, EED and UBC, are associated with epigenetic mechanisms, for
example histone modifications. Our study identified several histone proteins were also
significantly downregulated in the ET-1 treated fetal cardiomyocytes. These proteins
include: HIST1H2BA, HIST1H2BB, HIST1H3I, HIST2H3A, and HIST4H4. Histone
proteins are an essential component of chromatin. The biosynthesis of these proteins is
tightly linked to the cell cycle (Ewen, 2000; Ma et al., 2000; Zhao et al., 2000); as DNA
replicates, more histone proteins must also be produced (Osley, 1991). The ET-1
treatment induced decrease in histone protein expression supports our previous (Paradis
et al., 2014) evidence that ET-1 treated fetal cardiomyocytes prematurely exit the cell
cycle. If these cells are no longer actively cycling, then reduced histone production may
occur.
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A third convergence point of interactions between proteins is found in the upper
left corner of the merged network map (Figure 4.1). These proteins are key players
involved in proliferation and the cell cycle, including: ERK1/2, p38 MAPK, Akt, and
RhoA. These proteins are shown to have many interactions with others in the network
(Figure 4.9). One such protein is vimentin, a key structural protein that is associated with
RhoA signaling. Eriksson et al. reviews the topic of vimentin and RhoA interaction and
suggests that the outcome of RhoA-mediated signaling is dependent on the presence and
organization of vimentin (Eriksson et al., 2009). Furthermore, several diseases caused by
mutations in lamin A/C are shown to have defective MAPK and Akt signaling cascades
(Carmosino et al., 2014). It is possible that changes in lamin A/C expression would alter
the structure of the nuclear envelope and thus disrupt ERK1/2 activity and its
downstream cascade (Carmosino et al., 2014). Considering the crucial role that ERK1/2,
MAPK, and Akt play in cell survival and proliferation, it is likely that the dysregulation
of structural proteins such as lamin A/C can alter the signaling pathways of the before
mentioned proteins and thus decrease proliferation. Moreover, our previous work has
found that ET-1 induces a decrease in proliferation of fetal cardiomyocytes (Paradis et
al., 2014). Therefore these proliferation-involved proteins may provide a mechanism
through which ET-1 induces its functional changes.
A fourth convergence point on the merged map (Figure 4.1) is localized to the
plasma membrane, surrounding EGFR (epidermal growth factor receptor). The proteins
that are interacting with EGFR are depicted in Figure 4.10. Activation of the epidermal
growth factor receptor results in a signaling cascade that leads to cell proliferation.
Particularly in the cardiomyocyte, this pathway is crucial to their function and survival
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(Sridharan et al., 2013). Mutations in this receptor as well as its closely related family
members, has been shown to result in dilated cardiomyopathy (Crone et al., 2002; GarciaRivello et al., 2005; Ozcelik et al., 2002). Studies evaluating the developmental role of
the EGFR family of receptors have found that it is essential for cardiac development and
muscle differentiation (Garcia-Rivello et al., 2005; Gassmann et al., 1995). Mutations in
this family of receptors cause lethality during mid-embryogenesis most likely due to a
lack of cardiac trabeculae (Gassmann et al., 1995; K. F. Lee et al., 1995). These studies
suggest that EGFR and its family of receptors are essential to cardiac development and
may implicate this pathway in the regulation of the ET-1-induced effects on the
cardiomyocyte.
The expression of several proteins involved in post-transcriptional and posttranslational modifications were also differentially regulated by ET-1 treatment. Our
previous work has shown that ET-1 treatment leads to an increase in global DNA
methylation of fetal cardiomyocytes and in the presence of a DNA methylation inhibitor
the ET-1 induced premature terminal differentiation was also blocked (Paradis et al.,
2014). Together these findings suggest that several routes of epigenetic mechanisms may
be involved in cardiomyocyte maturation. This finding may further implicate the
involvement of the EED protein considering its role in transcriptional regulation via
epigenetic modifications. As part of the PRC2 complex, EED has been shown to utilize
histone modifications in order to suppress various developmental regulators that would
otherwise promote cell differentiation (T. I. Lee et al., 2006). In the context of the
developing heart, this may suggest that the EED protein is increased during early heart
development when proliferation is high. However as the heart nears maturation, it is
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likely that EED becomes downregulated to allow for differentiation to occur. ET-1 is
shown to accelerate terminal differentiation (Paradis et al., 2014), and based on our
current data ET-1 treatment may decrease EED levels in order to promote differentiation
and maturation of the heart.
ET-1 treatment of fetal cardiomyocytes also led to a downregulation of
cytoskeletal and contractile proteins, many of which have been associated with cardiac
disease. Several of the proteins identified in this present study are known to be associated
with heart disease such as, 1) hypertrophic cardiomyopathy (cardiac troponin I, titin, αtropomyosin, and α-actin) and 2) dilated cardiomyopathy (actin, tropomyosin, troponin I
and C, titin, desmin, and LIM protein) (Harvey & Leinwand, 2011; Wieczorek,
Jagatheesan, & Rajan, 2008).
Our present work found that tropomyosin alpha and beta were both
downregulated due to ET-1. Previous work has shown that a mutation in α-tropomyosin
leads to hypertrophic cardiomyopathy and cardiac dysfunction (Coviello et al., 1997;
Wieczorek et al., 2008). Another form of heart disease, dilated cardiomyopathy, can also
result from a mutation in tropomyosin (Rajan et al., 2010; Wieczorek et al., 2008).
Likewise, the loss of actin has been implicated in heart disease and failure (Olson,
Michels, Thibodeau, Tai, & Keating, 1998; Stefani et al., 2008). Thus, the
downregulation of these proteins due to ET-1 treatment may predispose the heart to
cardiovascular dysfunction and disease.
Mutations in titin, a large sarcomeric protein, have been associated with increased
incidence of dilated cardiomyopathy (Herman et al., 2012; McNally, 2012). Therefore a
decrease in titin function is implicated in contractile dysfunction and disease. Our study
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also revealed that vimentin, a cytoskeletal component, was significantly downregulated
due to ET-1 treatment. This protein is detected in developing muscle however not in
muscle that has become terminally differentiated (Eriksson et al., 2009; Gard, Bell, &
Lazarides, 1979; Granger & Lazarides, 1979), which supports our previous work (Paradis
et al., 2014) showing ET-1’s ability to promote terminal differentiation of
cardiomyocytes.
Another structural protein identified in our study, which plays a crucial role in
cardiomyocyte function, is Lamin A/C. Dilated cardiomyopathy has been observed in
mice with lamin A/C mutations (Mounkes, Kozlov, Rottman, & Stewart, 2005; Nikolova
et al., 2004; van Berlo, Duboc, & Pinto, 2004) and the cardiomyocytes of these hearts
have increased fragility and abnormal nuclear structure (Nikolova et al., 2004). Along
with dilated cardiomyopathy, a specific lamin A/C mutation resulted in early death due to
arrhythmia (Mounkes et al., 2005). A review of the literature by Carmosino et al. on the
role of lamin A/C in cardiomyocyte functions, implies that a decrease in lamin A/C
expression is key in promoting cardiomyocyte senescence (Carmosino et al., 2014).
Altogether these studies imply that lower levels of lamin A/C can result in cardiac disease
(Carmosino et al., 2014). Therefore, our present work suggests that ET-1 treatment
results in a significant decrease in lamin A/C expression and may result in a
predisposition to cardiovascular disease.
The major intermediate filament in cardiomyocytes (Tokuyasu, Maher, Dutton, &
Singer, 1985), desmin, has been shown to interact with lamin A/C (Carmosino et al.,
2014). Increased disorganization of desmin filaments is observed in lamin A/C mutations
of the heart (Nikolova et al., 2004; Sebillon et al., 2003). Desmin mutations have also
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been associated with dilated cardiomyopathy (Wang et al., 2001). Desmin-related
myopathies are characterized by desmin aggregates (Abraham et al., 1998) and this
aberrant aggregation is shown to lead to desmin network disruption, abnormal nuclear
shape, and cardiac dysfunction (Wang et al., 2001; Wang, Osinska, Gerdes, & Robbins,
2002).
The present study examined the ET-1 induced changes in the fetal cardiomyocyte
proteome. Our proteomic analyses revealed a number of proteins that may be involved in
the ET-1-induced terminal differentiation process previously described (Paradis et al.,
2014). Based on our pathway analysis, many of these proteins are associated with
pathways that regulate proliferation and survival of cardiomyocytes. Furthermore, many
of the proteins identified are known to be downregulated in heart disease, implying that
these young hearts may be more susceptible to disease. The results of this study provide
supporting evidence to pursue several avenues of protein interactions in order to identify
the molecular mechanism behind the ET-1-induced premature terminal differentiation of
cardiomyocytes.
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CHAPTER FIVE
GENERAL DISCUSSION
Potential Mediators of Premature Terminal Differentiation
Hypoxia is a far too common stress to the developing fetus. A key mediator of the
effects of hypoxia is endothelin-1 (ET-1). The gene for this small peptide contains a
hypoxia-response element (Hu et al., 1998; Kakinuma et al., 2001; Minchenko & Caro,
2000) and thus becomes quickly elevated under a low oxygen environment. Therefore,
this present work hypothesized that ET-1 is intermediating the hypoxia/anoxia-induced
terminal differentiation of cardiomyocytes. Prepro-ET-1 is significantly increased under
hypoxia and anoxia as was shown in chapters two and three. Furthermore by blocking the
ET-receptors (both selectively and non-selectively), the hypoxia/anoxia-induced effects
were abrogated, providing further evidence for ET-1 as a key downstream regulator.
As described in chapters two and three, hypoxia and anoxia treatment lead to a
significant decrease in the proliferation of cardiomyocytes. The endowment of this
functional unit of the heart during the critical stage of development can have a major
impact on the overall function of the heart. Both in vitro hypoxia and in vivo anoxia
treatment significantly reduced the percentage of proliferating cardiomyocytes. Similarly,
treatment of fetal cardiomyocytes versus neonatal rats yielded the same effects on
cardiomyocyte proliferation. Together, this suggests a true effect of hypoxia on
cardiomyocyte proliferation, regardless of the method of treatment used.
Interestingly, the in vitro and in vivo model of hypoxia/anoxia had different
results in regards to the percent of binucleation. The in vitro treatment of fetal
cardiomyocytes with hypoxia or ET-1 led to a significant increase in binucleation.

116#

However the in vivo anoxia model did not yield the same result; the percent of
binucleation was not changed in this case. This difference may be due to a variety of
differences in experimental design. Other studies have also shown an increase in
binucleation of fetal cardiomyocytes (Bae et al., 2003; Jonker et al., 2010) however
studies have not been performed in neonatal cardiomyocytes previously. Furthermore, the
in vitro culture treatment versus in vivo treatment may explain the differential
binucleation results. These two forms of treatment may elicit very different effects on the
cardiomyocyte. The in vitro treatment showed the direct effect of ET-1 on the maturation
of fetal cardiomyocytes, which lead to increased binucleation. However, the in vivo
model was utilized to simulate the anoxic episodes that often occur in preterm newborns.
In this model, there are many other factors other than ET-1 involved and thus these
factors may be counteracting ET-1 s direct effect on binucleation.
Much evidence from the studies laid out in chapters two and three indicate that
the endothelin-receptor is a key mediator of the hypoxia/anoxia-induced effects. A nonselective ET-receptor antagonist (PD145065) was utilized in the in vitro studies and it
was found to block the effects of the ET-1 treatment. Subsequently, the selective ETAreceptor (PD156707) was able to abrogate the anoxia-induced effects on proliferation.
The ETA-receptor is the predominant subtype found in cardiomyocytes (Kohan et al.,
2011) and thus of particular interest for these studies. Although the receptor density was
unchanged in the neonatal heart treated with anoxia, the inhibition of this receptor
abrogated the anoxia-induced effects on the heart.
In chapter three, the results showed that anoxia treatment led to an increase in p27
expression and decrease in cyclin D2 expression. The p27 protein associated with cyclin
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and cyclin-dependent kinase complexes and inhibits their activity. In this way, p27 works
to regulate the cell cycle and control cell proliferation (Ishida, Kitagawa, Hatakeyama, &
Nakayama, 2000). Normally, the amount of p27 is increased during G0-G1 phase, when
p27 translation and protein stability is maximal (Wander, Zhao, & Slingerland, 2011), but
then decreases upon entry into S phase (Nourse et al., 1994). This cell cycle inhibitor,
p27, is predominantly regulated by post-translational modifications (Hengst & Reed,
1996; Pagano et al., 1995). One common modification is phosphorylation, which
regulates the stability, localization, and function of p27 (Wander et al., 2011).
Phosphorylation at a certain residue can stabilize the p27 protein and is more commonly
observed in cells found in the G0 or G1 phase of the cell cycle (Ishida et al., 2000).
Although the expression of phosphorylated p27 protein was not measured in the present
studies, it is likely that the expression of this form would also be significantly altered in
mature cardiomyocytes. Terminally differentiated cardiomyocytes have significantly
decreased expression of Ki-67, a protein that is expressed in every phase of the cell cycle
except for the G0 phase. Therefore these mature cardiomyocytes are not actively dividing
and have exited the cell cycle and now reside in the G0 phase. Seeing that adult
cardiomyocytes are terminally differentiated and that there is an increase in p27
expression, it leads us to presume that the levels of the phosphorylated form would also
be altered.
Another post-translational modification that modulates p27 expression is
ubiquitination. The degradation of p27 can be achieved through both the ubiquitinproteasome pathway and ubiquitin-independent proteolytic cleavage (Shirane et al.,
1999). The ubiquitination of p27 has been observed to be lower during the G0/G1 phase as
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compared to the G1/S transition (Shirane et al., 1999). Thus it is possible that an increase
in terminal differentiation of cardiomyocytes may coincide with a decrease in p27
ubiquitination. Ubiquitin protein C (UBC) is a key protein that interacted with numerous
other proteins identified in the proteomics study outlined in chapter four. UBC appears to
interact with a majority of the proteins identified in the pathway analysis, suggesting that
ubiquitination is a key mechanism involved in the differential expression of these
proteins following ET-1 treatment. UBC expression itself was not measured in the
present studies but it is likely that UBC’s interaction with p27 may be reduced while its
interaction with other proteins may increase, resulting in terminally differentiated
cardiomyocytes.
The expression and role of p27 and cyclin D2 is inversely correlated, as implied
by the results in chapter three. In fact, it has been suggested that cyclin D2 plays a key
role in p27 downregulation during the transition from the G0 to G1 phase (Susaki,
Nakayama, & Nakayama, 2007). Cyclin D2 can mediate the translocation of p27 from the
nucleus to the cytoplasm were p27 degradation then takes place (Susaki et al., 2007). Our
results show that p27 expression is increased while cyclin D2 expression is decreased due
to anoxia treatment. This may suggest that an alternative explanation for increased p27
expression is due to the corresponding decrease in cyclin D2. Without as much cyclin D2
present, the p27 is not rapidly translocated to the cytoplasm for degradation and thus it
can elicit its inhibitory effects on the cell cycle.
The proteomics analysis in chapter four also revealed an interaction between a
number of proteins involved in proliferation and cell survival, such as Akt, ERK1//2, and
p38 MAPK. The proliferation pathway in cardiomyocytes is initiated by several signaling
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mechanisms involving the PI3K/Akt and Ras/ERK pathways (Ahuja, Perriard, et al.,
2007; Kang & Sucov, 2005; Sucov, Gu, Thomas, Li, & Pashmforoush, 2009; Tseng et al.,
2005). Data from Lee et al. suggests that activation of ERK and Akt pathways can lead to
the phosphorylation and degradation of p27 (J. G. Lee & Kay, 2011). The expression of
p27 was found to be downstream of the ERK pathway (Gysin, Lee, Dean, & McMahon,
2005), and the inhibition of p27 would lead to greater cell proliferation. Inhibition of the
ERK pathway thus results in greater expression of the cell cycle inhibitor, p27 (Gysin et
al., 2005). In the light of our present work, these studies may suggest that the ERK
pathway is diminished due to hypoxia/anoxia treatment.
Several studies have shown that Akt can phosphorylate p27 at several residues
and subsequently abolish the function of the cell cycle inhibitor (Fujita, Sato, Katayama,
& Tsuruo, 2002; Liang et al., 2002). Akt activation can also lead to increased FOXO
(Forkhead O) transcription factors, followed by decreased p27 expression and increased
cardiomyocyte proliferation (Evans-Anderson, Alfieri, & Yutzey, 2008). Together, these
studies imply that the Akt pathway is closely involved in the proliferation of
cardiomyocytes via the regulation of the cell cycle inhibitor p27. Chapters two and three
of this present study showed that cardiomyocyte proliferation is decreased while p27
expression is increased. Furthermore, chapter four provided evidence that both the ERK
and Akt pathways may be key players in the mechanism leading to ET-1-induced
premature terminal differentiation.

Implications of an Altered Cardiomyocyte Population
Proper cardiomyocyte endowment is a crucial component in establishing a
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fortified heart that can function properly for a lifetime. The present work provides
evidence that an anoxia-induced premature terminal differentiation may reduce
cardiomyocyte endowment. Based on the field of Developmental Origins of Health and
Disease, it is well established that stresses in utero can alter the structure and function of
organs, predisposing them to disease later in life. The developing heart is no exception.
The functional unit of the heart, the cardiomyocyte, is necessary in providing the
contractile force to pump blood throughout the body. Therefore if the structure and
function of the cardiomyocytes become altered, then the overall function of the heart
would consequentially be affected. Hearts of these individuals may have decreased
cardiac function and be unable to cope with stress later in life.
Porello et al. have shown that a decrease in the population of cardiomyocytes in
the neonate has a great impact on the adult heart. Later in life, the less populated hearts
may be more vulnerable to situations where there is increased stress or workload
(Porrello et al., 2009; Porrello, Widdop, & Delbridge, 2008). Studies by this group have
also suggested that adult cardiac hypertrophy originates in early neonatal development
when cardiomyocyte growth is altered (Porrello et al., 2009). Dysregulated trophic
signaling, such as through increased PI3K or suppressed MAPK activation, have been
associated with the establishment of cardiac hypertrophy (Porrello et al., 2009). Previous
work from our lab has shown that prenatal hypoxia increases the susceptibility of the
heart to ischemia-reperfusion injury in adulthood (G. Li et al., 2003). Together these
studies suggest that the cardiomyocyte population determined during the perinatal period
is essential to the proper structure and function of the adult heart. A reduced
cardiomyocyte population will increase the vulnerability of that heart to disease
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throughout its life, especially if it encounters a secondary stress in adulthood.
There are a number of factors that can determine cardiomyocyte endowment,
including: hormones and signaling pathways related to proliferation, apoptosis, and of
course the timing of terminal differentiation (Botting et al., 2012). Based on the present
study, hypoxia/anoxia and the downstream ET-1 appear to also be involved in regulating
the endowment of cardiomyocytes. This work found that anoxia treatment leads to a
significant decrease in proliferation during early neonatal time-points followed by an
ultimate reduction in cardiomyocyte endowment by neonatal day 14. By the end of the
first two neonatal weeks, the heart is presumed to be fully mature and like that of an adult
heart. Therefore, neonatal anoxia treatment alters the rate of proliferation, which
ultimately alters the number of cardiomyocytes per weight of the adult heart.

Potential Epigenetic Mechanisms Involved in Premature
Terminal Differentiation
The perinatal environment can elicit its effects on the development of an organ
via epigenetic mechanisms. The work presented here provides evidence that two of the
major epigenetic mechanisms, DNA methylation and histone modifications, are involved
in the premature terminal differentiation of cardiomyocytes. ET-1 treated fetal
cardiomyocytes had a significant increase in global DNA methylation, as shown in
chapter two. The increase in global DNA methylation was associated with an accelerated
cardiomyocyte terminal differentiation. Previous work by Kou et al. has shown that the
first two weeks of neonatal life when cardiomyocytes normally transition to the
terminally differentiated form is correlated with an increase in DNA methylation (Kou et
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al., 2010). Altogether suggesting that a hypermethylated genome is associated with the
terminal differentiation of cardiomyocytes (Kou et al., 2010). Our results using the DNA
methylation inhibitor, 5-aza-2’-deoxycytidine, provide further evidence for this
phenomenon. Following the addition of 5-aza-2’-deoxycytidine, ET-1’s effect on
cardiomyocyte binucleation and proliferation were also blocked. Therefore suggesting
that DNA methylation is a mechanism by which ET-1 induces a premature terminal
differentiation of cardiomyocytes. Although global DNA methylation was not measured
in chapter three, we presume that the anoxia-induced premature terminal differentiation
would be associated with a hypermethylated genome. Anoxia is shown to induce ET-1
and if this peptide acts through DNA methylation to alter terminal differentiation, then
we presume simulating anoxia itself would result in the same effect.
At this point, no specific methylation studies have been done however it is
possible that two of the cell cycle genes, p27 and cyclin D2, are being differentially
methylated. The expression of these two proteins are inversely correlated and tightly
involved in regulating the cell cycle and hence proliferation and terminal differentiation.
Studies have found that the p27 and cyclin D2 genes are located in the same gene cluster
(Ansari-Lari et al., 1998; Qian, Jin, & Lloyd, 2000). This gene cluster consists of many
regulatory genes including those involved in cell proliferation, and it is found on human
chromosome 12p13 as well as its syntenic regions on mouse and rat chromosomes
(Ansari-Lari et al., 1998). Due to the location of these genes in the same gene cluster, it
has been suggested that there is a common regulatory mechanism due to shared
regulatory elements (Qian et al., 2000). One possible regulatory mechanism may be DNA
methylation or histone modifications modulating the expression of these two genes.
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However, considering the fact that these two cell cycle genes are inversely
correlated, it is possible that different regulatory mechanisms are involved. The
expression of p27 appears to be increased under circumstances that promote terminal
differentiation while the expression of cyclin D2 is decreased. Therefore, differential
methylation of these two regions may be occurring. It is also possible that histone
modifications are differentially activating the transcription of p27 and repressing the
transcription of cyclin D2 under hypoxic/anoxic conditions that stimulate terminal
differentiation.
Interestingly, the expression of several histone proteins was decreased in ET-1
treated fetal cardiomyocytes, as described in chapter four. This finding may suggest that
the DNA is more unwound and less compact following ET-1 treatment. Histones play a
key role in winding DNA to condense and compact the genome. In order for transcription
to occur, the DNA must be unwound from the histones so that the transcription
machinery can access the genes. Therefore a decrease in the expression of histones may
suggest that the DNA is unwound and allowing greater access for transcription to occur.
Terminal differentiation is likely associated with a decrease in the transcription of several
proliferative and cell cycle genes while the transcription of genes associated with
differentiation is increased. Therefore certain regions of the genome may be less compact
due to a loss of histone proteins and result in increased transcription of those regions.
Subsequently, while a decrease in histone proteins may result in a less compacted
genome, there is also an increase in global DNA methylation. In this way certain genes,
particularly those related to proliferation, may still be “turned off”#to allow terminal
differentiation to occur.

124#

Regardless of the expression of histones, modification of these proteins may also
be regulating the period of terminal differentiation. The PRC2 complex, of which EED is
a crucial subunit, is involved in histone modifications and subsequent gene silencing (T.
I. Lee et al., 2006). EED was identified in the proteomics analysis to be a key mediator in
the ET-1 induced terminal differentiation of cardiomyocyte. The PRC2 complex is
particularly involved in retaining the cell in a proliferative state by silencing genes related
to cell differentiation. Although the expression of EED was not measured, it is likely that
its expression is decreased as the cell transitions to a terminally differentiated form.
Overall, the present study suggests that many epigenetic mechanisms are involved
in regulating this critical period of terminal differentiation. Future studies will be needed
to elucidate this intricate mechanism further.

Conclusion
The perinatal environment is one that is experienced by every single individual.
One of the most detrimental and far too common insults during this time is hypoxia. This
environmental stress during the crucial period of development can have lasting effects on
the structure and function of an individual throughout life. This present study provides
evidence for the damaging effects of hypoxia/anoxia on the cardiomyocyte population in
the heart. Hypoxia/anoxia treatment decreases cardiomyocyte proliferation and ultimately
leads to premature terminal differentiation and reduced cardiomyocyte endowment in the
adult heart. This present work identified a novel mechanism by which ET-1 is a key
mediator of the effects of hypoxia/anoxia on cardiomyocyte development, more
specifically via the ETA-receptor. Furthermore, this work illuminates several regulatory
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mechanisms and potential molecular pathways involved in the process of premature
terminal differentiation. This process appears to be linked to cell cycle genes, such as p27
and cyclin D2, as well as several epigenetic mechanisms. Global DNA methylation is
enhanced due to ET-1 treatment and when this mechanism becomes abrogated, the ET-1
induced terminal differentiation is also blocked. The findings presented here also
implicate the expression and epigenetic modification of histone proteins as potential
mechanisms in the hypoxia/ET-1-induced premature terminal differentiation of
cardiomyocytes. In addition, a proteomics analysis of proteins differentially regulated and
potentially involved in the ET-1 induced terminal differentiation will allow future studies
to further elucidate the mechanism behind this process. Future studies will be imperative
considering the importance of optimizing the development and endowment of
cardiomyocytes in the heart at an early stage.
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Figure 5.1. Summary of the effects of ET-1 on cardiomyocyte maturation. The
effect of hypoxia/anoxia exposure on cardiomyocytes is mediated by endothelin-1
(ET-1). Varying effects were observed in fetal cardiomyocytes treated ex vivo and
neonatal cardiomyocytes treated in vivo. ET-1-treated fetal cardiomyocytes had
increased binucleation, decreased proliferation, increased global DNA methylation,
and a significantly altered proteomic profile. The in vivo neonatal anoxia model also
resulted in a decrease in proliferation as well as a significant reduction in
cardiomyocyte endowment in the day 14 heart.

127#

REFERENCES
Abraham, S. C., DeNofrio, D., Loh, E., Minda, J. M., Tomaszewski, J. E., Pietra, G. G.,
& Reynolds, C. (1998). Desmin myopathy involving cardiac, skeletal, and
vascular smooth muscle: report of a case with immunoelectron microscopy. Hum
Pathol, 29(8), 876-882.
Agapitov, A. V., & Haynes, W. G. (2002). Role of endothelin in cardiovascular disease. J
Renin Angiotensin Aldosterone Syst, 3(1), 1-15. doi: 10.3317/jraas.2002.001
Ahuja, P., Perriard, E., Pedrazzini, T., Satoh, S., Perriard, J. C., & Ehler, E. (2007). Reexpression of proteins involved in cytokinesis during cardiac hypertrophy. Exp
Cell Res, 313(6), 1270-1283. doi: 10.1016/j.yexcr.2007.01.009
Ahuja, P., Sdek, P., & MacLellan, W. R. (2007). Cardiac myocyte cell cycle control in
development, disease, and regeneration. Physiol Rev, 87(2), 521-544. doi:
10.1152/physrev.00032.2006
Anatskaya, O. V., & Vinogradov, A. E. (2007). Genome multiplication as adaptation to
tissue survival: evidence from gene expression in mammalian heart and liver.
Genomics, 89(1), 70-80. doi: 10.1016/j.ygeno.2006.08.014
Ansari-Lari, M. A., Oeltjen, J. C., Schwartz, S., Zhang, Z., Muzny, D. M., Lu, J., . . .
Gibbs, R. A. (1998). Comparative sequence analysis of a gene-rich cluster at
human chromosome 12p13 and its syntenic region in mouse chromosome 6.
Genome Res, 8(1), 29-40.
Arai, H., Hori, S., Aramori, I., Ohkubo, H., & Nakanishi, S. (1990). Cloning and
expression of a cDNA encoding an endothelin receptor. Nature, 348(6303), 730732. doi: 10.1038/348730a0
Bae, S., Xiao, Y., Li, G., Casiano, C. A., & Zhang, L. (2003). Effect of maternal chronic
hypoxic exposure during gestation on apoptosis in fetal rat heart. Am J Physiol
Heart Circ Physiol, 285(3), H983-990. doi: 10.1152/ajpheart.00005.2003
Banerjee, I., Fuseler, J. W., Price, R. L., Borg, T. K., & Baudino, T. A. (2007).
Determination of cell types and numbers during cardiac development in the
neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol, 293(3),
H1883-1891. doi: 10.1152/ajpheart.00514.2007
Barker, D. J. (1990). The fetal and infant origins of adult disease. BMJ, 301(6761), 1111.
Barker, D. J. (1995). Fetal origins of coronary heart disease. BMJ, 311(6998), 171-174.
Barker, D. J. (1997). Fetal nutrition and cardiovascular disease in later life. Br Med Bull,
53(1), 96-108.

128#

Barker, D. J. (2004). The developmental origins of chronic adult disease. Acta Paediatr
Suppl, 93(446), 26-33.
Barker, D. J., & Osmond, C. (1986). Infant mortality, childhood nutrition, and ischaemic
heart disease in England and Wales. Lancet, 1(8489), 1077-1081.
Barton, M., & Yanagisawa, M. (2008). Endothelin: 20 years from discovery to therapy.
Can J Physiol Pharmacol, 86(8), 485-498. doi: 10.1139/y08-059
Bateson, P., Barker, D., Clutton-Brock, T., Deb, D., D'Udine, B., Foley, R. A., . . . Sultan,
S. E. (2004). Developmental plasticity and human health. Nature, 430(6998), 419421. doi: 10.1038/nature02725
Beigi, F., Schmeckpeper, J., Pow-Anpongkul, P., Payne, J. A., Zhang, L., Zhang, Z., . . .
Dzau, V. J. (2013). C3orf58, a Novel Paracrine Protein, Stimulates
Cardiomyocyte Cell-Cycle Progression Through the PI3K-AKT-CDK7 Pathway.
Circ Res, 113(4), 372-380. doi: 10.1161/circresaha.113.301075
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabe-Heider, F., Walsh, S., .
. . Frisen, J. (2009). Evidence for cardiomyocyte renewal in humans. Science,
324(5923), 98-102. doi: 10.1126/science.1164680
Bolivar, J. M., Gerhardt, T., Gonzalez, A., Hummler, H., Claure, N., Everett, R., &
Bancalari, E. (1995). Mechanisms for episodes of hypoxemia in preterm infants
undergoing mechanical ventilation. J Pediatr, 127(5), 767-773.
Botting, K. J., McMillen, I. C., Forbes, H., Nyengaard, J. R., & Morrison, J. L. (2014).
Chronic hypoxemia in late gestation decreases cardiomyocyte number but does
not change expression of hypoxia-responsive genes. J Am Heart Assoc, 3(4). doi:
10.1161/jaha.113.000531
Botting, K. J., Wang, K. C., Padhee, M., McMillen, I. C., Summers-Pearce, B.,
Rattanatray, L., . . . Morrison, J. L. (2012). Early origins of heart disease: low
birth weight and determinants of cardiomyocyte endowment. Clin Exp Pharmacol
Physiol, 39(9), 814-823. doi: 10.1111/j.1440-1681.2011.05649.x
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., . . .
Jaenisch, R. (2006). Polycomb complexes repress developmental regulators in
murine embryonic stem cells. Nature, 441(7091), 349-353. doi:
10.1038/nature04733
Brooks, G., Poolman, R. A., & Li, J. M. (1998). Arresting developments in the cardiac
myocyte cell cycle: role of cyclin-dependent kinase inhibitors. Cardiovasc Res,
39(2), 301-311.
Bubb, K. J., Cock, M. L., Black, M. J., Dodic, M., Boon, W. M., Parkington, H. C., . . .
Tare, M. (2007). Intrauterine growth restriction delays cardiomyocyte maturation

129#

and alters coronary artery function in the fetal sheep. J Physiol, 578(Pt 3), 871881. doi: 10.1113/jphysiol.2006.121160
Bugaisky, L., & Zak, R. (1979). Cellular growth of cardiac muscle after birth. Tex Rep
Biol Med, 39, 123-138.
Burrell, J. H., Boyn, A. M., Kumarasamy, V., Hsieh, A., Head, S. I., & Lumbers, E. R.
(2003). Growth and maturation of cardiac myocytes in fetal sheep in the second
half of gestation. Anat Rec A Discov Mol Cell Evol Biol, 274(2), 952-961. doi:
10.1002/ar.a.10110
Carmosino, M., Torretta, S., Procino, G., Gerbino, A., Forleo, C., Favale, S., & Svelto,
M. (2014). Role of nuclear Lamin A/C in cardiomyocyte functions. Biol Cell,
106(10), 346-358. doi: 10.1111/boc.201400033
Ceccarelli, F., Scavuzzo, M. C., Giusti, L., Bigini, G., Costa, B., Carnicelli, V., . . .
Mazzoni, M. R. (2003). ETA receptor-mediated Ca2+ mobilisation in H9c2
cardiac cells. Biochem Pharmacol, 65(5), 783-793.
Chen, H. W., Yu, S. L., Chen, W. J., Yang, P. C., Chien, C. T., Chou, H. Y., . . . Lee, Y.
T. (2004). Dynamic changes of gene expression profiles during postnatal
development of the heart in mice. Heart, 90(8), 927-934. doi:
10.1136/hrt.2002.006734
Chlopcikova, S., Psotova, J., & Miketova, P. (2001). Neonatal rat cardiomyocytes--a
model for the study of morphological, biochemical and electrophysiological
characteristics of the heart. Biomed Pap Med Fac Univ Palacky Olomouc Czech
Repub, 145(2), 49-55.
Chu, W., Wan, L., Zhao, D., Qu, X., Cai, F., Huo, R., . . . Yang, B. (2012). Mild hypoxiainduced cardiomyocyte hypertrophy via up-regulation of HIF-1alpha-mediated
TRPC signalling. J Cell Mol Med, 16(9), 2022-2034. doi: 10.1111/j.15824934.2011.01497.x
Clubb, F. J., Jr., & Bishop, S. P. (1984). Formation of binucleated myocardial cells in the
neonatal rat. An index for growth hypertrophy. Lab Invest, 50(5), 571-577.
Coe, Y., Haleen, S. J., Welch, K. M., Liu, Y. A., & Coceani, F. (2002). The endothelin A
receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the
hypoxic pulmonary vasoconstriction in the perinatal lamb. J Pharmacol Exp Ther,
302(2), 672-680.
Cooper, A. L., & Beasley, D. (1999). Hypoxia stimulates proliferation and interleukin1alpha production in human vascular smooth muscle cells. Am J Physiol, 277(4 Pt
2), H1326-1337.
Corstius, H. B., Zimanyi, M. A., Maka, N., Herath, T., Thomas, W., van der Laarse, A., .
. . Black, M. J. (2005). Effect of intrauterine growth restriction on the number of
130#

cardiomyocytes in rat hearts. Pediatr Res, 57(6), 796-800. doi:
10.1203/01.pdr.0000157726.65492.cd
Coviello, D. A., Maron, B. J., Spirito, P., Watkins, H., Vosberg, H. P., Thierfelder, L., . . .
Seidman, C. E. (1997). Clinical features of hypertrophic cardiomyopathy caused
by mutation of a "hot spot" in the alpha-tropomyosin gene. J Am Coll Cardiol,
29(3), 635-640.
Crone, S. A., Zhao, Y. Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., . . . Lee, K. F.
(2002). ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med,
8(5), 459-465. doi: 10.1038/nm0502-459
Cullingford, T. E., Markou, T., Fuller, S. J., Giraldo, A., Pikkarainen, S., Zoumpoulidou,
G., . . . Clerk, A. (2008). Temporal regulation of expression of immediate early
and second phase transcripts by endothelin-1 in cardiomyocytes. Genome Biol,
9(2), R32. doi: 10.1186/gb-2008-9-2-r32
Delgado-Olguin, P., Huang, Y., Li, X., Christodoulou, D., Seidman, C. E., Seidman, J.
G., . . . Bruneau, B. G. (2012). Epigenetic repression of cardiac progenitor gene
expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet,
44(3), 343-347. doi: 10.1038/ng.1068
Di Stefano, V., Giacca, M., Capogrossi, M. C., Crescenzi, M., & Martelli, F. (2011).
Knockdown of cyclin-dependent kinase inhibitors induces cardiomyocyte re-entry
in the cell cycle. J Biol Chem, 286(10), 8644-8654. doi:
10.1074/jbc.M110.184549
Dimaguila, M. A., Di Fiore, J. M., Martin, R. J., & Miller, M. J. (1997). Characteristics of
hypoxemic episodes in very low birth weight infants on ventilatory support. J
Pediatr, 130(4), 577-583.
Doherty, A. M., Cody, W. L., He, J. X., DePue, P. L., Cheng, X. M., Welch, K. M., . . . et
al. (1993). In vitro and in vivo studies with a series of hexapeptide endothelin
antagonists. J Cardiovasc Pharmacol, 22 Suppl 8, S98-102.
Dransfield, D. A., Spitzer, A. R., & Fox, W. W. (1983). Episodic airway obstruction in
premature infants. Am J Dis Child, 137(5), 441-443.
Drimal, J., Knezl, V., Drimal, J., Jr., Drimal, D., Bauerova, K., Kettmann, V., . . . Stefek,
M. (2003). Cardiac effects of endothelin-1 (ET-1) and related C terminal peptide
fragment: increased inotropy or contribution to heart failure? Physiol Res, 52(6),
701-708.
Engel, F. B., Schebesta, M., & Keating, M. T. (2006). Anillin localization defect in
cardiomyocyte binucleation. J Mol Cell Cardiol, 41(4), 601-612. doi:
10.1016/j.yjmcc.2006.06.012

131#

Eriksson, J. E., Dechat, T., Grin, B., Helfand, B., Mendez, M., Pallari, H. M., &
Goldman, R. D. (2009). Introducing intermediate filaments: from discovery to
disease. J Clin Invest, 119(7), 1763-1771. doi: 10.1172/jci38339
Evans-Anderson, H. J., Alfieri, C. M., & Yutzey, K. E. (2008). Regulation of
cardiomyocyte proliferation and myocardial growth during development by
FOXO transcription factors. Circ Res, 102(6), 686-694. doi:
10.1161/circresaha.107.163428
Ewen, M. E. (2000). Where the cell cycle and histones meet. Genes Dev, 14(18), 22652270.
Fernandez-Patron, C., Radomski, M. W., & Davidge, S. T. (1999). Vascular matrix
metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor.
Circ Res, 85(10), 906-911.
Fujita, N., Sato, S., Katayama, K., & Tsuruo, T. (2002). Akt-dependent phosphorylation
of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol
Chem, 277(32), 28706-28713. doi: 10.1074/jbc.M203668200
Gao, Y., & Raj, J. U. (2010). Regulation of the pulmonary circulation in the fetus and
newborn. Physiol Rev, 90(4), 1291-1335. doi: 10.1152/physrev.00032.2009
Garcia-Rivello, H., Taranda, J., Said, M., Cabeza-Meckert, P., Vila-Petroff, M.,
Scaglione, J., . . . Hertig, C. M. (2005). Dilated cardiomyopathy in Erb-b4deficient ventricular muscle. Am J Physiol Heart Circ Physiol, 289(3), H11531160. doi: 10.1152/ajpheart.00048.2005
Gard, D. L., Bell, P. B., & Lazarides, E. (1979). Coexistence of desmin and the
fibroblastic intermediate filament subunit in muscle and nonmuscle cells:
identification and comparative peptide analysis. Proc Natl Acad Sci U S A, 76(8),
3894-3898.
Gardner, L. B., Li, F., Yang, X., & Dang, C. V. (2003). Anoxic fibroblasts activate a
replication checkpoint that is bypassed by E1a. Mol Cell Biol, 23(24), 9032-9045.
Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., & Lemke, G.
(1995). Aberrant neural and cardiac development in mice lacking the ErbB4
neuregulin receptor. Nature, 378(6555), 390-394. doi: 10.1038/378390a0
George, E. M., & Granger, J. P. (2011). Endothelin: key mediator of hypertension in
preeclampsia. Am J Hypertens, 24(9), 964-969. doi: 10.1038/ajh.2011.99
Giaccia, A. J., Simon, M. C., & Johnson, R. (2004). The biology of hypoxia: the role of
oxygen sensing in development, normal function, and disease. Genes Dev, 18(18),
2183-2194. doi: 10.1101/gad.1243304

132#

Giraud, G. D., Louey, S., Jonker, S., Schultz, J., & Thornburg, K. L. (2006). Cortisol
stimulates cell cycle activity in the cardiomyocyte of the sheep fetus.
Endocrinology, 147(8), 3643-3649. doi: 10.1210/en.2006-0061
Gluckman, P. D., Hanson, M. A., Cooper, C., & Thornburg, K. L. (2008). Effect of in
utero and early-life conditions on adult health and disease. N Engl J Med, 359(1),
61-73. doi: 10.1056/NEJMra0708473
Goda, N., Dozier, S. J., & Johnson, R. S. (2003). HIF-1 in cell cycle regulation,
apoptosis, and tumor progression. Antioxid Redox Signal, 5(4), 467-473. doi:
10.1089/152308603768295212
Goda, N., Ryan, H. E., Khadivi, B., McNulty, W., Rickert, R. C., & Johnson, R. S.
(2003). Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during
hypoxia. Mol Cell Biol, 23(1), 359-369.
Goldie, R. G. (1999). Endothelins in health and disease: an overview. Clin Exp
Pharmacol Physiol, 26(2), 145-148.
Granger, B. L., & Lazarides, E. (1979). Desmin and vimentin coexist at the periphery of
the myofibril Z disc. Cell, 18(4), 1053-1063.
Gysin, S., Lee, S. H., Dean, N. M., & McMahon, M. (2005). Pharmacologic inhibition of
RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through
induced expression of p27Kip1. Cancer Res, 65(11), 4870-4880. doi:
10.1158/0008-5472.can-04-2848
Hammoud, L., Burger, D. E., Lu, X., & Feng, Q. (2009). Tissue inhibitor of
metalloproteinase-3 inhibits neonatal mouse cardiomyocyte proliferation via
EGFR/JNK/SP-1 signaling. Am J Physiol Cell Physiol, 296(4), C735-745. doi:
10.1152/ajpcell.00246.2008
Hammoud, L., Xiang, F., Lu, X., Brunner, F., Leco, K., & Feng, Q. (2007). Endothelial
nitric oxide synthase promotes neonatal cardiomyocyte proliferation by inhibiting
tissue inhibitor of metalloproteinase-3 expression. Cardiovasc Res, 75(2), 359368. doi: 10.1016/j.cardiores.2007.05.006
Harvey, P. A., & Leinwand, L. A. (2011). The cell biology of disease: cellular
mechanisms of cardiomyopathy. J Cell Biol, 194(3), 355-365. doi:
10.1083/jcb.201101100
Hashiguchi, K., Takagi, K., Nakabayashi, M., Takeda, Y., Sakamoto, S., Naruse, M., . . .
Demura, H. (1991). Relationship between fetal hypoxia and endothelin-1 in fetal
circulation. J Cardiovasc Pharmacol, 17 Suppl 7, S509-510.
He, A., Ma, Q., Cao, J., von Gise, A., Zhou, P., Xie, H., . . . Pu, W. T. (2012). Polycomb
repressive complex 2 regulates normal development of the mouse heart. Circ Res,
110(3), 406-415. doi: 10.1161/circresaha.111.252205
133#

Hengst, L., & Reed, S. I. (1996). Translational control of p27Kip1 accumulation during
the cell cycle. Science, 271(5257), 1861-1864.
Herman, D. S., Lam, L., Taylor, M. R., Wang, L., Teekakirikul, P., Christodoulou, D., . .
. Seidman, C. E. (2012). Truncations of titin causing dilated cardiomyopathy. N
Engl J Med, 366(7), 619-628. doi: 10.1056/NEJMoa1110186
Hosoda, K., Nakao, K., Hiroshi, A., Suga, S., Ogawa, Y., Mukoyama, M., . . . Imura, H.
(1991). Cloning and expression of human endothelin-1 receptor cDNA. FEBS
Lett, 287(1-2), 23-26.
Howard, P. G., Plumpton, C., & Davenport, A. P. (1992). Anatomical localization and
pharmacological activity of mature endothelins and their precursors in human
vascular tissue. J Hypertens, 10(11), 1379-1386.
Hu, J., Discher, D. J., Bishopric, N. H., & Webster, K. A. (1998). Hypoxia regulates
expression of the endothelin-1 gene through a proximal hypoxia-inducible factor1 binding site on the antisense strand. Biochem Biophys Res Commun, 245(3),
894-899. doi: 10.1006/bbrc.1998.8543
Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K., & Masaki,
T. (1989). The human endothelin family: three structurally and pharmacologically
distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A,
86(8), 2863-2867.
Ishida, N., Kitagawa, M., Hatakeyama, S., & Nakayama, K. (2000). Phosphorylation at
serine 10, a major phosphorylation site of p27(Kip1), increases its protein
stability. J Biol Chem, 275(33), 25146-25154. doi: 10.1074/jbc.M001144200
Ito, H., Adachi, S., Tamamori, M., Fujisaki, H., Tanaka, M., Lin, M., . . . Hiroe, M.
(1996). Mild hypoxia induces hypertrophy of cultured neonatal rat
cardiomyocytes: a possible endogenous endothelin-1-mediated mechanism. J Mol
Cell Cardiol, 28(6), 1271-1277. doi: 10.1006/jmcc.1996.0117
Ito, H., Hirata, Y., Hiroe, M., Tsujino, M., Adachi, S., Takamoto, T., . . . Marumo, F.
(1991). Endothelin-1 induces hypertrophy with enhanced expression of musclespecific genes in cultured neonatal rat cardiomyocytes. Circ Res, 69(1), 209-215.
Jensen, G. M., & Moore, L. G. (1997). The effect of high altitude and other risk factors
on birthweight: independent or interactive effects? Am J Public Health, 87(6),
1003-1007.
Jeyabalan, A., Novak, J., Danielson, L. A., Kerchner, L. J., Opett, S. L., & Conrad, K. P.
(2003). Essential role for vascular gelatinase activity in relaxin-induced renal
vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries.
Circ Res, 93(12), 1249-1257. doi: 10.1161/01.res.0000104086.43830.6c

134#

Jonker, S. S., Giraud, M. K., Giraud, G. D., Chattergoon, N. N., Louey, S., Davis, L. E., .
. . Thornburg, K. L. (2010). Cardiomyocyte enlargement, proliferation and
maturation during chronic fetal anaemia in sheep. Exp Physiol, 95(1), 131-139.
doi: 10.1113/expphysiol.2009.049379
Jopling, C., Sleep, E., Raya, M., Marti, M., Raya, A., & Izpisua Belmonte, J. C. (2010).
Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and
proliferation. Nature, 464(7288), 606-609. doi: 10.1038/nature08899
Jopling, C., Sune, G., Faucherre, A., Fabregat, C., & Izpisua Belmonte, J. C. (2012).
Hypoxia induces myocardial regeneration in zebrafish. Circulation, 126(25),
3017-3027. doi: 10.1161/circulationaha.112.107888
Kakinuma, Y., Miyauchi, T., Yuki, K., Murakoshi, N., Goto, K., & Yamaguchi, I. (2001).
Novel molecular mechanism of increased myocardial endothelin-1 expression in
the failing heart involving the transcriptional factor hypoxia-inducible factor1alpha induced for impaired myocardial energy metabolism. Circulation, 103(19),
2387-2394.
Kang, J. O., & Sucov, H. M. (2005). Convergent proliferative response and divergent
morphogenic pathways induced by epicardial and endocardial signaling in fetal
heart development. Mech Dev, 122(1), 57-65. doi: 10.1016/j.mod.2004.09.001
Kawanabe, Y., & Nauli, S. M. (2011). Endothelin. Cell Mol Life Sci, 68(2), 195-203. doi:
10.1007/s00018-010-0518-0
Kedzierski, R. M., & Yanagisawa, M. (2001). Endothelin system: the double-edged
sword in health and disease. Annu Rev Pharmacol Toxicol, 41, 851-876. doi:
10.1146/annurev.pharmtox.41.1.851
Kelly, J. J., & Whitworth, J. A. (1999). Endothelin-1 as a mediator in cardiovascular
disease. Clin Exp Pharmacol Physiol, 26(2), 158-161.
Kido, M., Du, L., Sullivan, C. C., Li, X., Deutsch, R., Jamieson, S. W., & Thistlethwaite,
P. A. (2005). Hypoxia-inducible factor 1-alpha reduces infarction and attenuates
progression of cardiac dysfunction after myocardial infarction in the mouse. J Am
Coll Cardiol, 46(11), 2116-2124. doi: 10.1016/j.jacc.2005.08.045
Kohan, D. E., Rossi, N. F., Inscho, E. W., & Pollock, D. M. (2011). Regulation of blood
pressure and salt homeostasis by endothelin. Physiol Rev, 91(1), 1-77. doi:
10.1152/physrev.00060.2009
Komuro, I., Kurihara, H., Sugiyama, T., Yoshizumi, M., Takaku, F., & Yazaki, Y.
(1988). Endothelin stimulates c-fos and c-myc expression and proliferation of
vascular smooth muscle cells. FEBS Lett, 238(2), 249-252.

135#

Kou, C. Y., Lau, S. L., Au, K. W., Leung, P. Y., Chim, S. S., Fung, K. P., . . . Tsui, S. K.
(2010). Epigenetic regulation of neonatal cardiomyocytes differentiation.
Biochem Biophys Res Commun, 400(2), 278-283. doi: 10.1016/j.bbrc.2010.08.064
Lee, J. G., & Kay, E. P. (2011). PI 3-kinase/Rac1 and ERK1/2 regulate FGF-2-mediated
cell proliferation through phosphorylation of p27 at Ser10 by KIS and at Thr187
by Cdc25A/Cdk2. Invest Ophthalmol Vis Sci, 52(1), 417-426. doi:
10.1167/iovs.10-6140
Lee, K. F., Simon, H., Chen, H., Bates, B., Hung, M. C., & Hauser, C. (1995).
Requirement for neuregulin receptor erbB2 in neural and cardiac development.
Nature, 378(6555), 394-398. doi: 10.1038/378394a0
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R. M., . . .
Young, R. A. (2006). Control of developmental regulators by Polycomb in human
embryonic stem cells. Cell, 125(2), 301-313. doi: 10.1016/j.cell.2006.02.043
Li, F., Wang, X., Capasso, J. M., & Gerdes, A. M. (1996). Rapid transition of cardiac
myocytes from hyperplasia to hypertrophy during postnatal development. J Mol
Cell Cardiol, 28(8), 1737-1746. doi: 10.1006/jmcc.1996.0163
Li, G., Bae, S., & Zhang, L. (2004). Effect of prenatal hypoxia on heat stress-mediated
cardioprotection in adult rat heart. Am J Physiol Heart Circ Physiol, 286(5),
H1712-1719. doi: 10.1152/ajpheart.00898.2003
Li, G., Xiao, Y., Estrella, J. L., Ducsay, C. A., Gilbert, R. D., & Zhang, L. (2003). Effect
of fetal hypoxia on heart susceptibility to ischemia and reperfusion injury in the
adult rat. J Soc Gynecol Investig, 10(5), 265-274.
Li, H., Chen, S. J., Chen, Y. F., Meng, Q. C., Durand, J., Oparil, S., & Elton, T. S.
(1994). Enhanced endothelin-1 and endothelin receptor gene expression in
chronic hypoxia. J Appl Physiol, 77(3), 1451-1459.
Li, X., Wei, X. L., Meng, L. L., Chi, M. G., Yan, J. Q., Ma, X. Y., . . . Zheng, J. Q.
(2009). Involvement of tissue transglutaminase in endothelin 1-induced
hypertrophy in cultured neonatal rat cardiomyocytes. Hypertension, 54(4), 839844. doi: 10.1161/hypertensionaha.109.130161
Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., . . .
Slingerland, J. M. (2002). PKB/Akt phosphorylates p27, impairs nuclear import
of p27 and opposes p27-mediated G1 arrest. Nat Med, 8(10), 1153-1160. doi:
10.1038/nm761
Liu, Y., Tang, M. K., Cai, D. Q., Li, M., Wong, W. M., Chow, P. H., & Lee, K. K.
(2007). Cyclin I and p53 are differentially expressed during the terminal
differentiation of the postnatal mouse heart. Proteomics, 7(1), 23-32. doi:
10.1002/pmic.200600456

136#

Liu, Z., Yue, S., Chen, X., Kubin, T., & Braun, T. (2010). Regulation of cardiomyocyte
polyploidy and multinucleation by CyclinG1. Circ Res, 106(9), 1498-1506. doi:
10.1161/circresaha.109.211888
Louey, S., Jonker, S. S., Giraud, G. D., & Thornburg, K. L. (2007). Placental
insufficiency decreases cell cycle activity and terminal maturation in fetal sheep
cardiomyocytes. J Physiol, 580(Pt. 2), 639-648. doi:
10.1113/jphysiol.2006.122200
Ma, T., Van Tine, B. A., Wei, Y., Garrett, M. D., Nelson, D., Adams, P. D., . . . Harper, J.
W. (2000). Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin
E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev, 14(18),
2298-2313.
Majumdar, P., Chen, S., George, B., Sen, S., Karmazyn, M., & Chakrabarti, S. (2009).
Leptin and endothelin-1 mediated increased extracellular matrix protein
production and cardiomyocyte hypertrophy in diabetic heart disease. Diabetes
Metab Res Rev, 25(5), 452-463. doi: 10.1002/dmrr.964
Martin, R. J., Wang, K., Koroglu, O., Di Fiore, J., & Kc, P. (2011). Intermittent hypoxic
episodes in preterm infants: do they matter? Neonatology, 100(3), 303-310. doi:
10.1159/000329922
Matsuyama, D., & Kawahara, K. (2011). Oxidative stress-induced formation of a
positive-feedback loop for the sustained activation of p38 MAPK leading to the
loss of cell division in cardiomyocytes soon after birth. Basic Res Cardiol, 106(5),
815-828. doi: 10.1007/s00395-011-0178-8
McCullough, R. E., Reeves, J. T., & Liljegren, R. L. (1977). Fetal growth retardation and
increased infant mortality at high altitude. Obstet Gynecol Surv, 32(7), 596-598.
McNally, E. M. (2012). Genetics: broken giant linked to heart failure. Nature, 483(7389),
281-282. doi: 10.1038/483281a
Meyer, K., Zhang, H., & Zhang, L. (2009). Direct effect of cocaine on epigenetic
regulation of PKCepsilon gene repression in the fetal rat heart. J Mol Cell
Cardiol, 47(4), 504-511. doi: 10.1016/j.yjmcc.2009.06.004
Minchenko, A., & Caro, J. (2000). Regulation of endothelin-1 gene expression in human
microvascular endothelial cells by hypoxia and cobalt: role of hypoxia responsive
element. Mol Cell Biochem, 208(1-2), 53-62.
Moore, L. G. (2003). Fetal growth restriction and maternal oxygen transport during high
altitude pregnancy. High Alt Med Biol, 4(2), 141-156. doi:
10.1089/152702903322022767
Morrison, J. L., Botting, K. J., Dyer, J. L., Williams, S. J., Thornburg, K. L., &
McMillen, I. C. (2007). Restriction of placental function alters heart development
137#

in the sheep fetus. Am J Physiol Regul Integr Comp Physiol, 293(1), R306-313.
doi: 10.1152/ajpregu.00798.2006
Mounkes, L. C., Kozlov, S. V., Rottman, J. N., & Stewart, C. L. (2005). Expression of an
LMNA-N195K variant of A-type lamins results in cardiac conduction defects and
death in mice. Hum Mol Genet, 14(15), 2167-2180. doi: 10.1093/hmg/ddi221
Nakas-Icindic, E., Zaciragic, A., Hadzovic, A., & Avdagic, N. (2004). Endothelin in
health and disease. Bosn J Basic Med Sci, 4(3), 31-34.
Nikolova, V., Leimena, C., McMahon, A. C., Tan, J. C., Chandar, S., Jogia, D., . . .
Fatkin, D. (2004). Defects in nuclear structure and function promote dilated
cardiomyopathy in lamin A/C-deficient mice. J Clin Invest, 113(3), 357-369. doi:
10.1172/jci19448
Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M. H., . . . Roberts, J.
M. (1994). Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent
kinase inhibitor prevented by rapamycin. Nature, 372(6506), 570-573. doi:
10.1038/372570a0
O'Neill, T. J. t., Mack, C. P., & Taylor, J. M. (2012). Germline deletion of FAK-related
non-kinase delays post-natal cardiomyocyte mitotic arrest. J Mol Cell Cardiol,
53(2), 156-164. doi: 10.1016/j.yjmcc.2012.04.007
Olson, T. M., Michels, V. V., Thibodeau, S. N., Tai, Y. S., & Keating, M. T. (1998).
Actin mutations in dilated cardiomyopathy, a heritable form of heart failure.
Science, 280(5364), 750-752.
Osley, M. A. (1991). The regulation of histone synthesis in the cell cycle. Annu Rev
Biochem, 60, 827-861. doi: 10.1146/annurev.bi.60.070191.004143
Ostlund, E., Lindholm, H., Hemsen, A., & Fried, G. (2000). Fetal erythropoietin and
endothelin-1: relation to hypoxia and intrauterine growth retardation. Acta Obstet
Gynecol Scand, 79(4), 276-282.
Ozcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hubner, N., . . . Garratt,
A. N. (2002). Conditional mutation of the ErbB2 (HER2) receptor in
cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A,
99(13), 8880-8885. doi: 10.1073/pnas.122249299
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., . . .
Rolfe, M. (1995). Role of the ubiquitin-proteasome pathway in regulating
abundance of the cyclin-dependent kinase inhibitor p27. Science, 269(5224), 682685.
Paradis, A., Xiao, D., Zhou, J., & Zhang, L. (2014). Endothelin-1 Promotes
Cardiomyocyte Terminal Differentiation in the Developing Heart via Heightened
DNA Methylation. Int J Med Sci, 11(4), 373-380. doi: 10.7150/ijms.7802
138#

Pasumarthi, K. B., & Field, L. J. (2002). Cardiomyocyte cell cycle regulation. Circ Res,
90(10), 1044-1054.
Patterson, A. J., Chen, M., Xue, Q., Xiao, D., & Zhang, L. (2010). Chronic prenatal
hypoxia induces epigenetic programming of PKC{epsilon} gene repression in rat
hearts. Circ Res, 107(3), 365-373. doi: 10.1161/circresaha.110.221259
Patterson, A. J., Xiao, D., Xiong, F., Dixon, B., & Zhang, L. (2012). Hypoxia-derived
oxidative stress mediates epigenetic repression of PKCepsilon gene in foetal rat
hearts. Cardiovasc Res, 93(2), 302-310. doi: 10.1093/cvr/cvr322
Perreault, T., & Coceani, F. (2003). Endothelin in the perinatal circulation. Can J Physiol
Pharmacol, 81(6), 644-653. doi: 10.1139/y03-013
Ponicke, K., Vogelsang, M., Heinroth, M., Becker, K., Zolk, O., Bohm, M., . . . Brodde,
O. E. (1998). Endothelin receptors in the failing and nonfailing human heart.
Circulation, 97(8), 744-751.
Porrello, E. R., Bell, J. R., Schertzer, J. D., Curl, C. L., McMullen, J. R., Mellor, K. M., .
. . Delbridge, L. M. (2009). Heritable pathologic cardiac hypertrophy in adulthood
is preceded by neonatal cardiac growth restriction. Am J Physiol Regul Integr
Comp Physiol, 296(3), R672-680. doi: 10.1152/ajpregu.90919.2008
Porrello, E. R., Widdop, R. E., & Delbridge, L. M. (2008). Early origins of cardiac
hypertrophy: does cardiomyocyte attrition programme for pathological 'catch-up'
growth of the heart? Clin Exp Pharmacol Physiol, 35(11), 1358-1364. doi:
10.1111/j.1440-1681.2008.05036.x
Qian, X., Jin, L., & Lloyd, R. V. (2000). Aberrant DNA methylation of cyclin D2 and
p27 genes in rodent pituitary tumor cell lines correlates with specific gene
expression. Endocr Pathol, 11(1), 85-96.
Radom-Aizik, S., Zaldivar, F. P., Nance, D. M., Haddad, F., Cooper, D. M., & Adams, G.
R. (2013). Growth inhibition and compensation in response to neonatal hypoxia in
rats. Pediatr Res, 74(2), 111-120. doi: 10.1038/pr.2013.80
Rajan, S., Jagatheesan, G., Karam, C. N., Alves, M. L., Bodi, I., Schwartz, A., . . .
Wieczorek, D. F. (2010). Molecular and functional characterization of a novel
cardiac-specific human tropomyosin isoform. Circulation, 121(3), 410-418. doi:
10.1161/circulationaha.109.889725
Rautureau, Y., & Schiffrin, E. L. (2012). Endothelin in hypertension: an update. Curr
Opin Nephrol Hypertens, 21(2), 128-136. doi: 10.1097/MNH.0b013e32834f0092
Ream, M., Ray, A. M., Chandra, R., & Chikaraishi, D. M. (2008). Early fetal hypoxia
leads to growth restriction and myocardial thinning. Am J Physiol Regul Integr
Comp Physiol, 295(2), R583-595. doi: 10.1152/ajpregu.00771.2007

139#

Reynolds, E. E., Keiser, J. A., Haleen, S. J., Walker, D. M., Olszewski, B., Schroeder, R.
L., . . . et al. (1995). Pharmacological characterization of PD 156707, an orally
active ETA receptor antagonist. J Pharmacol Exp Ther, 273(3), 1410-1417.
Rubanyi, G. M., & Polokoff, M. A. (1994). Endothelins: molecular biology,
biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev,
46(3), 325-415.
Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K., & Masaki,
T. (1990). Cloning of a cDNA encoding a non-isopeptide-selective subtype of the
endothelin receptor. Nature, 348(6303), 732-735. doi: 10.1038/348732a0
Sdek, P., Zhao, P., Wang, Y., Huang, C. J., Ko, C. Y., Butler, P. C., . . . Maclellan, W. R.
(2011). Rb and p130 control cell cycle gene silencing to maintain the postmitotic
phenotype in cardiac myocytes. J Cell Biol, 194(3), 407-423. doi:
10.1083/jcb.201012049
Sebillon, P., Bouchier, C., Bidot, L. D., Bonne, G., Ahamed, K., Charron, P., . . .
Komajda, M. (2003). Expanding the phenotype of LMNA mutations in dilated
cardiomyopathy and functional consequences of these mutations. J Med Genet,
40(8), 560-567.
Shirane, M., Harumiya, Y., Ishida, N., Hirai, A., Miyamoto, C., Hatakeyama, S., . . .
Kitagawa, M. (1999). Down-regulation of p27(Kip1) by two mechanisms,
ubiquitin-mediated degradation and proteolytic processing. J Biol Chem, 274(20),
13886-13893.
Shubeita, H. E., McDonough, P. M., Harris, A. N., Knowlton, K. U., Glembotski, C. C.,
Brown, J. H., & Chien, K. R. (1990). Endothelin induction of inositol
phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in
ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J
Biol Chem, 265(33), 20555-20562.
Simard, E., Jin, D., Takai, S., Miyazaki, M., Brochu, I., & D'Orleans-Juste, P. (2009).
Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J
Pharmacol Exp Ther, 328(2), 540-548. doi: 10.1124/jpet.108.142992
Sridharan, V., Sharma, S. K., Moros, E. G., Corry, P. M., Tripathi, P., Lieblong, B. J., . . .
Boerma, M. (2013). Effects of radiation on the epidermal growth factor receptor
pathway in the heart. Int J Radiat Biol, 89(7), 539-547. doi:
10.3109/09553002.2013.782110
Stefani, M., Tsubakihara, M., Hambly, B., Liew, C., Allen, P., Macdonald, P., & dos
Remedios, C. (2008). Actin and Its Binding Proteins in Heart Failure. In C. dos
Remedios & D. Chhabra (Eds.), Actin-Binding Proteins and Disease (Vol. 8, pp.
318-334): Springer New York.

140#

Stein, A. B., Jones, T. A., Herron, T. J., Patel, S. R., Day, S. M., Noujaim, S. F., . . .
Dressler, G. R. (2011). Loss of H3K4 methylation destabilizes gene expression
patterns and physiological functions in adult murine cardiomyocytes. J Clin
Invest, 121(7), 2641-2650. doi: 10.1172/jci44641
Sucov, H. M., Gu, Y., Thomas, S., Li, P., & Pashmforoush, M. (2009). Epicardial control
of myocardial proliferation and morphogenesis. Pediatr Cardiol, 30(5), 617-625.
doi: 10.1007/s00246-009-9391-8
Sun, Q., Zhang, F., Wafa, K., Baptist, T., & Pasumarthi, K. B. (2009). A splice variant of
cyclin D2 regulates cardiomyocyte cell cycle through a novel protein aggregation
pathway. J Cell Sci, 122(Pt 10), 1563-1573. doi: 10.1242/jcs.047738
Susaki, E., Nakayama, K., & Nakayama, K. I. (2007). Cyclin D2 translocates p27 out of
the nucleus and promotes its degradation at the G0-G1 transition. Mol Cell Biol,
27(13), 4626-4640. doi: 10.1128/mcb.00862-06
Suzuki, T., Hoshi, H., & Mitsui, Y. (1990). Endothelin stimulates hypertrophy and
contractility of neonatal rat cardiac myocytes in a serum-free medium. FEBS Lett,
268(1), 149-151.
Thaete, L. G., Jilling, T., Synowiec, S., Khan, S., & Neerhof, M. G. (2007). Expression of
endothelin 1 and its receptors in the hypoxic pregnant rat. Biol Reprod, 77(3),
526-532. doi: 10.1095/biolreprod.107.061820
Thornburg, K., Jonker, S., O'Tierney, P., Chattergoon, N., Louey, S., Faber, J., & Giraud,
G. (2011). Regulation of the cardiomyocyte population in the developing heart.
Prog Biophys Mol Biol, 106(1), 289-299. doi: 10.1016/j.pbiomolbio.2010.11.010
Tokuyasu, K. T., Maher, P. A., Dutton, A. H., & Singer, S. J. (1985). Intermediate
filaments in skeletal and cardiac muscle tissue in embryonic and adult chicken.
Ann N Y Acad Sci, 455, 200-212.
Tong, W., Xiong, F., Li, Y., & Zhang, L. (2013). Hypoxia inhibits cardiomyocyte
proliferation in fetal rat hearts via upregulating TIMP-4. Am J Physiol Regul
Integr Comp Physiol. doi: 10.1152/ajpregu.00515.2012
Tong, W., Xue, Q., Li, Y., & Zhang, L. (2011). Maternal hypoxia alters matrix
metalloproteinase expression patterns and causes cardiac remodeling in fetal and
neonatal rats. Am J Physiol Heart Circ Physiol, 301(5), H2113-2121. doi:
10.1152/ajpheart.00356.2011
Tong, W., & Zhang, L. (2012). Fetal hypoxia and programming of matrix
metalloproteinases. Drug Discov Today, 17(3-4), 124-134. doi:
10.1016/j.drudis.2011.09.011
Tseng, Y. T., Yano, N., Rojan, A., Stabila, J. P., McGonnigal, B. G., Ianus, V., . . .
Padbury, J. F. (2005). Ontogeny of phosphoinositide 3-kinase signaling in
141#

developing heart: effect of acute beta-adrenergic stimulation. Am J Physiol Heart
Circ Physiol, 289(5), H1834-1842. doi: 10.1152/ajpheart.00435.2005
Vallender, T. W., & Lahn, B. T. (2006). Localized methylation in the key regulator gene
endothelin-1 is associated with cell type-specific transcriptional silencing. FEBS
Lett, 580(18), 4560-4566. doi: 10.1016/j.febslet.2006.07.017
van Berlo, J. H., Duboc, D., & Pinto, Y. M. (2004). Often seen but rarely recognised:
cardiac complications of lamin A/C mutations. Eur Heart J, 25(10), 812-814. doi:
10.1016/j.ehj.2004.03.007
von Gise, A., Lin, Z., Schlegelmilch, K., Honor, L. B., Pan, G. M., Buck, J. N., . . . Pu,
W. T. (2012). YAP1, the nuclear target of Hippo signaling, stimulates heart
growth through cardiomyocyte proliferation but not hypertrophy. Proc Natl Acad
Sci U S A, 109(7), 2394-2399. doi: 10.1073/pnas.1116136109
Wagner, O. F., Christ, G., Wojta, J., Vierhapper, H., Parzer, S., Nowotny, P. J., . . .
Binder, B. R. (1992). Polar secretion of endothelin-1 by cultured endothelial cells.
J Biol Chem, 267(23), 16066-16068.
Walsh, S., Ponten, A., Fleischmann, B. K., & Jovinge, S. (2010). Cardiomyocyte cell
cycle control and growth estimation in vivo--an analysis based on cardiomyocyte
nuclei. Cardiovasc Res, 86(3), 365-373. doi: 10.1093/cvr/cvq005
Wamstad, J. A., Alexander, J. M., Truty, R. M., Shrikumar, A., Li, F., Eilertson, K. E., . .
. Bruneau, B. G. (2012). Dynamic and coordinated epigenetic regulation of
developmental transitions in the cardiac lineage. Cell, 151(1), 206-220. doi:
10.1016/j.cell.2012.07.035
Wander, S. A., Zhao, D., & Slingerland, J. M. (2011). p27: a barometer of signaling
deregulation and potential predictor of response to targeted therapies. Clin Cancer
Res, 17(1), 12-18. doi: 10.1158/1078-0432.ccr-10-0752
Wang, X., Osinska, H., Dorn, G. W., 2nd, Nieman, M., Lorenz, J. N., Gerdes, A. M., . . .
Robbins, J. (2001). Mouse model of desmin-related cardiomyopathy. Circulation,
103(19), 2402-2407.
Wang, X., Osinska, H., Gerdes, A. M., & Robbins, J. (2002). Desmin filaments and
cardiac disease: establishing causality. J Card Fail, 8(6 Suppl), S287-292. doi:
10.1054/jcaf.2002.129279
Warner, T. D., Allcock, G. H., Corder, R., & Vane, J. R. (1993). Use of the endothelin
antagonists BQ-123 and PD 142893 to reveal three endothelin receptors
mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol,
110(2), 777-782.
Webster, W. S., & Abela, D. (2007). The effect of hypoxia in development. Birth Defects
Res C Embryo Today, 81(3), 215-228. doi: 10.1002/bdrc.20102
142#

Wei, C. M., Lerman, A., Rodeheffer, R. J., McGregor, C. G., Brandt, R. R., Wright, S., . .
. Burnett, J. C., Jr. (1994). Endothelin in human congestive heart failure.
Circulation, 89(4), 1580-1586.
Wieczorek, D. F., Jagatheesan, G., & Rajan, S. (2008). The role of tropomyosin in heart
disease. Adv Exp Med Biol, 644, 132-142.
Wilkes, B. M., Susin, M., & Mento, P. F. (1993). Localization of endothelin-1-like
immunoreactivity in human placenta. J Histochem Cytochem, 41(4), 535-541.
Xiao, D., Dasgupta, C., Chen, M., Zhang, K., Buchholz, J., Xu, Z., & Zhang, L. (2014).
Inhibition of DNA methylation reverses norepinephrine-induced cardiac
hypertrophy in rats. Cardiovasc Res, 101(3), 373-382. doi: 10.1093/cvr/cvt264
Xiao, D., Ducsay, C. A., & Zhang, L. (2000). Chronic hypoxia and developmental
regulation of cytochrome c expression in rats. J Soc Gynecol Investig, 7(5), 279283.
Xiao, Y., He, J., Gilbert, R. D., & Zhang, L. (2000). Cocaine induces apoptosis in fetal
myocardial cells through a mitochondria-dependent pathway. J Pharmacol Exp
Ther, 292(1), 8-14.
Xin, M., Kim, Y., Sutherland, L. B., Qi, X., McAnally, J., Schwartz, R. J., . . . Olson, E.
N. (2011). Regulation of insulin-like growth factor signaling by Yap governs
cardiomyocyte proliferation and embryonic heart size. Sci Signal, 4(196), ra70.
doi: 10.1126/scisignal.2002278
Xiong, F., Xiao, D., & Zhang, L. (2012). Norepinephrine causes epigenetic repression of
PKC{varepsilon} gene in rodent hearts by activating Nox1-dependent reactive
oxygen species production. FASEB J, 26(7), 2753-2763. doi: 10.1096/fj.11199422
Xiong, L., Darwanto, A., Sharma, S., Herring, J., Hu, S., Filippova, M., . . . Zhang, K.
(2011). Mass spectrometric studies on epigenetic interaction networks in cell
differentiation. J Biol Chem, 286(15), 13657-13668. doi:
10.1074/jbc.M110.204800
Xu, Y., Williams, S. J., O'Brien, D., & Davidge, S. T. (2006). Hypoxia or nutrient
restriction during pregnancy in rats leads to progressive cardiac remodeling and
impairs postischemic recovery in adult male offspring. FASEB J, 20(8), 12511253. doi: 10.1096/fj.05-4917fje
Xue, Q., Dasgupta, C., Chen, M., & Zhang, L. (2011). Foetal hypoxia increases cardiac
AT(2)R expression and subsequent vulnerability to adult ischaemic injury.
Cardiovasc Res, 89(2), 300-308. doi: 10.1093/cvr/cvq303

143#

Yamada, J., Fujimori, K., Ishida, T., Sanpei, M., Honda, S., & Sato, A. (2001). Plasma
endothelin-1 and atrial natriuretic peptide levels during prolonged (24-h) nonacidemic hypoxemia in fetal goats. J Matern Fetal Med, 10(6), 409-413.
Yamashita, K., Discher, D. J., Hu, J., Bishopric, N. H., & Webster, K. A. (2001).
Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of
hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol
Chem, 276(16), 12645-12653. doi: 10.1074/jbc.M011344200
Yanagisawa, M. (1994). The endothelin system. A new target for therapeutic
intervention. Circulation, 89(3), 1320-1322.
Yanagisawa, M., Inoue, A., Ishikawa, T., Kasuya, Y., Kimura, S., Kumagaye, S., . . . et
al. (1988). Primary structure, synthesis, and biological activity of rat endothelin,
an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A,
85(18), 6964-6967.
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., . . .
Masaki, T. (1988). A novel potent vasoconstrictor peptide produced by vascular
endothelial cells. Nature, 332(6163), 411-415. doi: 10.1038/332411a0
Yu, L., Li, M., She, T., Shi, C., Meng, W., Wang, B., & Cheng, M. (2013). Endothelin-1
Stimulates the Expression of L-Type Ca(2+) Channels in Neonatal Rat
Cardiomyocytes via the Extracellular Signal-Regulated Kinase 1/2 Pathway. J
Membr Biol, 246(4), 343-353. doi: 10.1007/s00232-013-9538-7
Zhang, F. X., Chen, M. L., Shan, Q. J., Zou, J. G., Chen, C., Yang, B., . . . Cao, K. J.
(2007). Hypoxia reoxygenation induces premature senescence in neonatal SD rat
cardiomyocytes. Acta Pharmacol Sin, 28(1), 44-51. doi: 10.1111/j.17457254.2007.00488.x
Zhang, K., Schrag, M., Crofton, A., Trivedi, R., Vinters, H., & Kirsch, W. (2012).
Targeted proteomics for quantification of histone acetylation in Alzheimer's
disease. Proteomics, 12(8), 1261-1268. doi: 10.1002/pmic.201200010
Zhang, L. (2005). Prenatal hypoxia and cardiac programming. J Soc Gynecol Investig,
12(1), 2-13. doi: 10.1016/j.jsgi.2004.09.004
Zhao, J., Kennedy, B. K., Lawrence, B. D., Barbie, D. A., Matera, A. G., Fletcher, J. A.,
& Harlow, E. (2000). NPAT links cyclin E-Cdk2 to the regulation of replicationdependent histone gene transcription. Genes Dev, 14(18), 2283-2297.
Zoabi, M., Sadeh, R., de Bie, P., Marquez, V. E., & Ciechanover, A. (2011). PRAJA1 is a
ubiquitin ligase for the polycomb repressive complex 2 proteins. Biochem
Biophys Res Commun, 408(3), 393-398. doi: 10.1016/j.bbrc.2011.04.025

144#

Zolk, O., Quattek, J., Sitzler, G., Schrader, T., Nickenig, G., Schnabel, P., . . . Bohm, M.
(1999). Expression of endothelin-1, endothelin-converting enzyme, and
endothelin receptors in chronic heart failure. Circulation, 99(16), 2118-2123.

145#

